File size: 218,134 Bytes
66ba51a |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818 2819 2820 2821 2822 2823 2824 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 2837 2838 2839 2840 2841 2842 2843 2844 2845 2846 2847 2848 2849 2850 2851 2852 2853 2854 2855 2856 2857 2858 2859 2860 2861 2862 2863 2864 2865 2866 2867 2868 2869 2870 2871 2872 2873 2874 2875 2876 2877 2878 2879 2880 2881 2882 2883 2884 2885 2886 2887 2888 2889 2890 2891 2892 2893 2894 2895 2896 2897 2898 2899 2900 2901 2902 2903 2904 2905 2906 2907 2908 2909 2910 2911 2912 2913 2914 2915 2916 2917 2918 2919 2920 2921 2922 2923 2924 2925 2926 2927 2928 2929 2930 2931 2932 2933 2934 2935 2936 2937 2938 2939 2940 2941 2942 2943 2944 2945 2946 2947 2948 2949 2950 2951 2952 2953 2954 2955 2956 2957 2958 2959 2960 2961 2962 2963 2964 2965 2966 2967 2968 2969 2970 2971 2972 2973 2974 2975 2976 2977 2978 2979 2980 2981 2982 2983 2984 2985 2986 2987 2988 2989 2990 2991 2992 2993 2994 2995 2996 2997 2998 2999 3000 3001 3002 3003 3004 3005 3006 3007 3008 3009 3010 3011 3012 3013 3014 3015 3016 3017 3018 3019 3020 3021 3022 3023 3024 3025 3026 3027 3028 3029 3030 3031 3032 3033 3034 3035 3036 3037 3038 3039 3040 3041 3042 3043 3044 3045 3046 3047 3048 3049 3050 3051 3052 3053 3054 3055 3056 3057 3058 3059 3060 3061 3062 3063 3064 3065 3066 3067 3068 3069 3070 3071 3072 3073 3074 3075 3076 3077 3078 3079 3080 3081 3082 3083 3084 3085 3086 3087 3088 3089 3090 3091 3092 3093 3094 3095 3096 3097 3098 3099 3100 3101 3102 3103 3104 3105 3106 3107 3108 3109 3110 3111 3112 3113 3114 3115 3116 3117 3118 3119 3120 3121 3122 3123 3124 3125 3126 3127 3128 3129 3130 3131 3132 3133 3134 3135 3136 3137 3138 3139 3140 3141 3142 3143 3144 3145 3146 3147 3148 3149 3150 3151 3152 3153 3154 3155 3156 3157 3158 3159 3160 3161 3162 3163 3164 3165 3166 3167 3168 3169 3170 3171 3172 3173 3174 3175 3176 3177 3178 3179 3180 3181 3182 3183 3184 3185 3186 3187 3188 3189 3190 3191 3192 3193 3194 3195 3196 3197 3198 3199 3200 3201 3202 3203 3204 3205 3206 3207 3208 3209 3210 3211 3212 3213 3214 3215 3216 3217 3218 3219 3220 3221 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 3233 3234 3235 3236 3237 3238 3239 3240 3241 3242 3243 3244 3245 3246 3247 3248 3249 3250 3251 3252 3253 3254 3255 3256 3257 3258 3259 3260 3261 3262 3263 3264 3265 3266 3267 3268 3269 3270 3271 3272 3273 3274 3275 3276 3277 3278 3279 3280 3281 3282 3283 3284 3285 3286 3287 3288 3289 3290 3291 3292 3293 3294 3295 3296 3297 3298 3299 3300 3301 3302 3303 3304 3305 3306 3307 3308 3309 3310 3311 3312 3313 3314 3315 3316 3317 3318 3319 3320 3321 3322 3323 3324 3325 3326 3327 3328 3329 3330 3331 3332 3333 3334 3335 3336 3337 3338 3339 3340 3341 3342 3343 3344 3345 3346 3347 3348 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 3360 3361 3362 3363 3364 3365 3366 3367 3368 3369 3370 3371 3372 3373 3374 3375 3376 3377 3378 3379 3380 3381 3382 3383 3384 3385 3386 3387 3388 3389 3390 3391 3392 3393 3394 3395 3396 3397 3398 3399 3400 3401 3402 3403 3404 3405 3406 3407 3408 3409 3410 3411 3412 3413 3414 3415 3416 3417 3418 3419 3420 3421 3422 3423 3424 3425 3426 3427 3428 3429 3430 3431 3432 3433 3434 3435 3436 3437 3438 3439 3440 3441 3442 3443 3444 3445 3446 3447 3448 3449 3450 3451 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 3470 3471 3472 3473 3474 3475 3476 3477 3478 3479 3480 3481 3482 3483 3484 3485 3486 3487 3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 3531 3532 3533 3534 3535 3536 3537 3538 3539 3540 3541 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 3562 3563 3564 3565 3566 3567 3568 3569 3570 3571 3572 3573 3574 3575 3576 3577 3578 3579 3580 3581 3582 3583 3584 3585 3586 3587 3588 3589 3590 3591 3592 3593 3594 3595 3596 3597 3598 3599 3600 3601 3602 3603 3604 3605 3606 3607 3608 3609 3610 3611 3612 3613 3614 3615 3616 3617 3618 3619 3620 3621 3622 3623 3624 3625 3626 3627 3628 3629 3630 3631 3632 3633 3634 3635 3636 3637 3638 3639 3640 3641 3642 3643 3644 3645 3646 3647 3648 3649 3650 3651 3652 3653 3654 3655 3656 3657 3658 3659 3660 3661 3662 3663 3664 3665 3666 3667 3668 3669 3670 3671 3672 3673 3674 3675 3676 3677 3678 3679 3680 3681 3682 3683 3684 3685 3686 3687 3688 3689 3690 3691 3692 3693 3694 3695 3696 3697 3698 3699 3700 3701 3702 3703 3704 3705 3706 3707 3708 3709 3710 3711 3712 3713 3714 3715 3716 3717 3718 3719 3720 3721 3722 3723 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733 3734 3735 3736 3737 3738 3739 3740 3741 3742 3743 3744 3745 3746 3747 3748 3749 3750 3751 3752 3753 3754 3755 3756 3757 3758 3759 3760 3761 3762 3763 3764 3765 3766 3767 3768 3769 3770 3771 3772 3773 3774 3775 3776 3777 3778 3779 3780 3781 3782 3783 3784 3785 3786 3787 3788 3789 3790 3791 3792 3793 3794 3795 3796 3797 3798 3799 3800 3801 3802 3803 3804 3805 3806 3807 3808 3809 3810 3811 3812 3813 3814 3815 3816 3817 3818 3819 3820 3821 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 3838 3839 3840 3841 3842 3843 3844 3845 3846 3847 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 3858 3859 3860 3861 3862 3863 3864 3865 3866 3867 3868 3869 3870 3871 3872 3873 3874 3875 3876 3877 3878 3879 3880 3881 3882 3883 3884 3885 3886 3887 3888 3889 3890 3891 3892 3893 3894 3895 3896 3897 3898 3899 3900 3901 3902 3903 3904 3905 3906 3907 3908 3909 3910 3911 3912 3913 3914 3915 3916 3917 3918 3919 3920 3921 3922 3923 3924 3925 3926 3927 3928 3929 3930 3931 3932 3933 3934 3935 3936 3937 3938 3939 3940 3941 3942 3943 3944 3945 3946 3947 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 3985 3986 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 4062 4063 4064 4065 4066 4067 4068 4069 4070 4071 4072 4073 4074 4075 4076 4077 4078 4079 4080 4081 4082 4083 4084 4085 4086 4087 4088 4089 4090 4091 4092 4093 4094 4095 4096 4097 4098 4099 4100 4101 4102 4103 4104 4105 4106 4107 4108 4109 4110 4111 4112 4113 4114 4115 4116 4117 4118 4119 4120 4121 4122 4123 4124 4125 4126 4127 4128 4129 4130 4131 4132 4133 4134 4135 4136 4137 4138 4139 4140 4141 4142 4143 4144 4145 4146 4147 4148 4149 4150 4151 4152 4153 4154 4155 4156 4157 4158 4159 4160 4161 4162 4163 4164 4165 4166 4167 4168 4169 4170 4171 4172 4173 4174 4175 4176 4177 4178 4179 4180 4181 4182 4183 4184 4185 4186 4187 4188 4189 4190 4191 4192 4193 4194 4195 4196 4197 4198 4199 4200 4201 4202 4203 4204 4205 4206 4207 4208 4209 4210 4211 4212 4213 4214 4215 4216 4217 4218 4219 4220 4221 4222 4223 4224 4225 4226 4227 4228 4229 4230 4231 4232 4233 4234 4235 4236 4237 4238 4239 4240 4241 4242 4243 4244 4245 4246 4247 4248 4249 4250 4251 4252 4253 4254 4255 4256 4257 4258 4259 4260 4261 4262 4263 4264 4265 |
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<tmx version="1.4">
<header adminlang="en" creationdate="20200424T153633Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="mt">
<prop type="distributor">ELRC project</prop>
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Maligna aligner was used for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop>
<prop type="l1">mt</prop>
<prop type="l2">en</prop>
<prop type="lengthInTUs">472</prop>
<prop type="# of words in l1">7112</prop>
<prop type="# of words in l2">7562</prop>
<prop type="# of unique words in l1">1396</prop>
<prop type="# of unique words in l2">1577</prop>
</header>
<body>
<tu tuid="1">
<prop type="lengthRatio">0.6470588235294118</prop>
<tuv xml:lang="en">
<seg>its purity;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-purità tiegħu;</seg>
</tuv>
</tu>
<tu tuid="2">
<prop type="lengthRatio">1.0333333333333334</prop>
<tuv xml:lang="en">
<seg>Are there serious side effects?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hemm effetti sekondarji serji?</seg>
</tuv>
</tu>
<tu tuid="3">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Thousands of volunteers</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Eluf ta' voluntiera</seg>
</tuv>
</tu>
<tu tuid="4">
<prop type="lengthRatio">0.8395061728395061</prop>
<tuv xml:lang="en">
<seg>its ingredients, including its inactive ingredients or ‘excipients';</seg>
</tuv>
<tuv xml:lang="mt">
<seg>l-ingredjenti tiegħu, inkluż l-ingredjenti mhux attivi tiegħu jew l-"eċċipjenti";</seg>
</tuv>
</tu>
<tu tuid="5">
<prop type="lengthRatio">1.4285714285714286</prop>
<tuv xml:lang="en">
<seg>Does the vaccine seem to work?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin huwa sikur?</seg>
</tuv>
</tu>
<tu tuid="6">
<prop type="lengthRatio">1.140625</prop>
<tuv xml:lang="en">
<seg>How are the immune systems of the participants responding to the vaccine?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sistemi immuni tal-parteċipanti kif jirrispondu għall-vaċċin?</seg>
</tuv>
</tu>
<tu tuid="7">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>This involves tests in the laboratory and in animals.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jinvolvi testijiet fil-laboratorju u fl-annimali.</seg>
</tuv>
</tu>
<tu tuid="8">
<prop type="lengthRatio">0.9368421052631579</prop>
<tuv xml:lang="en">
<seg>These include the European Medicines Agency and other regulators in the EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jinkludu l-Aġenzija Ewropea għall-Mediċini u regolaturi oħrajn fil-pajjiżi tal-UE/taż-ŻEE.</seg>
</tuv>
</tu>
<tu tuid="9">
<prop type="lengthRatio">0.8372093023255814</prop>
<tuv xml:lang="en">
<seg>At the end of the testing programme, the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘marketing authorisation' application.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-aħħar tal-programm ta' ttestjar, l-iżviluppatur tal-vaċċin jissottometti r-riżultati lill-awtoritajiet regolatorji tal-mediċini fl-Ewropa bħala parti minn applikazzjoni ta' "awtorizzazzjoni għat-tqegħid fis-suq".</seg>
</tuv>
</tu>
<tu tuid="10">
<prop type="lengthRatio">0.9325842696629213</prop>
<tuv xml:lang="en">
<seg>This is followed by a clinical testing programme in humans, which can take around ten years from initial concept to authorisation and must adhere to strict standards.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jiġi segwit minn programm ta' ttestjar kliniku fil-bnedmin, li jista' jieħu sa għaxar snin mill-kunċett inizjali sal-awtorizzazzjoni u għandu jaderixxi ma' standards stretti.</seg>
</tuv>
</tu>
<tu tuid="11">
<prop type="lengthRatio">0.8085106382978723</prop>
<tuv xml:lang="en">
<seg>What are the most common side effects?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Liema huma l-effetti sekondarji l-aktar komuni?</seg>
</tuv>
</tu>
<tu tuid="12">
<prop type="lengthRatio">0.8224852071005917</prop>
<tuv xml:lang="en">
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-awtoritajiet regolatorji tal-mediċini jistgħu jagħmlu spezzjonijiet biex jiżguraw li l-informazzjoni li jipprovdi l-iżviluppatur tal-vaċċin hija ta' min joqgħod fuqha.</seg>
</tuv>
</tu>
<tu tuid="13">
<prop type="lengthRatio">0.9090909090909091</prop>
<tuv xml:lang="en">
<seg>The companies are required to conduct stringent testing, for which the acceptance criteria are pre-defined by the authorities, on each batch of vaccine released onto the EU market.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumpaniji huma meħtieġa jwettqu ttestjar strinġenti, li għalih, il-kriterji tal-aċċettazzjoni tiegħu jiġu definiti minn qabel mill-awtoritajiet, fuq kull lott ta' vaċċini rilaxxat fis-suq tal-UE.</seg>
</tuv>
</tu>
<tu tuid="14">
<prop type="lengthRatio">0.963855421686747</prop>
<tuv xml:lang="en">
<seg>This programme has to follow the procedures and protocols set by the regulators:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan il-programm għandu jsegwi l-proċeduri u l-protokolli stabbiliti mir-regolaturi:</seg>
</tuv>
</tu>
<tu tuid="15">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>how it is manufactured.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kif jiġi manifatturat.</seg>
</tuv>
</tu>
<tu tuid="16">
<prop type="lengthRatio">0.85</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel ma vaċċin ikun jista' jiġi approvat fl-UE, irid jgħaddi minn ittestjar rigoruż mill-iżviluppatur tiegħu, u mbagħad minn evalwazzjoni xjentifika mill-awtoritajiet regolatorji.</seg>
</tuv>
</tu>
<tu tuid="17">
<prop type="lengthRatio">1.4090909090909092</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Benefiċċji tat-tlaqqim</seg>
</tuv>
</tu>
<tu tuid="18">
<prop type="lengthRatio">0.8</prop>
<tuv xml:lang="en">
<seg>Testing includes checking the vaccine's quality:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ittestjar jinkludi li tiġi ċċekkjata l-kwalità tal-vaċċin:</seg>
</tuv>
</tu>
<tu tuid="19">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iżviluppatur tal-vaċċin jittestja l-vaċċin fi tliet fażijiet ta' provi kliniċi, b'numri akbar ta' persuni f'kull fażi.</seg>
</tuv>
</tu>
<tu tuid="20">
<prop type="lengthRatio">0.8857142857142857</prop>
<tuv xml:lang="en">
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-regolaturi jistgħu japprovaw il-vaċċin biss jekk l-evalwazzjoni xjentifika tar-riżultati tat-testijiet tiegħu turi li l- benefiċċji tal-vaċċin huma akbar mir-riskji tiegħu.</seg>
</tuv>
</tu>
<tu tuid="21">
<prop type="lengthRatio">0.5348837209302325</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="22">
<prop type="lengthRatio">0.8333333333333334</prop>
<tuv xml:lang="en">
<seg>Then the vaccine developer tests the vaccine's effects.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Imbagħad l-iżviluppatur tal-vaċċin jittestja l-effetti tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="23">
<prop type="lengthRatio">1.25</prop>
<tuv xml:lang="en">
<seg>What is the optimal dose?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-aħjar doża?</seg>
</tuv>
</tu>
<tu tuid="24">
<prop type="lengthRatio">0.9570552147239264</prop>
<tuv xml:lang="en">
<seg>They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jistgħu wkoll jagħmlu testijiet biex jiżguraw li l-lottijiet tal-vaċċini rilaxxati fis-suq ikunu tal-kwalità mistennija u jkunu ġew manifatturati kif suppost.</seg>
</tuv>
</tu>
<tu tuid="25">
<prop type="lengthRatio">0.6451612903225806</prop>
<tuv xml:lang="en">
<seg>Is the vaccine safe?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin jidher li qed jaħdem?</seg>
</tuv>
</tu>
<tu tuid="26">
<prop type="lengthRatio">0.9863013698630136</prop>
<tuv xml:lang="en">
<seg>Vaccination is the only way to ensure direct protection against tetanus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim huwa l-uniku mod li jiżgura protezzjoni diretta kontra t-tetnu.</seg>
</tuv>
</tu>
<tu tuid="27">
<prop type="lengthRatio">0.980544747081712</prop>
<tuv xml:lang="en">
<seg>For example, to ensure community immunity against measles, public health authorities recommend that 95% of the population are vaccinated with two doses of the vaccine against measles (the MMR vaccine, which protects against measles, mumps and rubella).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, biex jiżguraw l-immunità komunitarja kontra l-ħosba, l-awtoritajiet tas-saħħa pubblika jirrakkomandaw li 95 % tal-popolazzjoni jitlaqqmu b'żewġ dożi tal-vaċċin kontra l-ħosba (il-vaċċin MMR, li jipproteġi kontra l-ħosba, il-gattone u r-rubella).</seg>
</tuv>
</tu>
<tu tuid="28">
<prop type="lengthRatio">1.0292887029288702</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases, reducing the risk of diseases spreading among family members, school mates or colleagues, friends, neighbours and other people in the community.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-persuni mlaqqma u lill-persuni ta' madwarhom li huma vulnerabbli għall-mard, inaqqas ir-riskju li l-mard jinfirex fost il-membri tal-familja, ħbieb tal-iskola, kollegi, ħbieb, ġirien u persuni oħrajn fil-komunità.</seg>
</tuv>
</tu>
<tu tuid="29">
<prop type="lengthRatio">0.8351648351648352</prop>
<tuv xml:lang="en">
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din hija magħrufa bħala "immunità komunitarja" (li tissejjaħ ukoll "immunità bħala grupp").</seg>
</tuv>
</tu>
<tu tuid="30">
<prop type="lengthRatio">0.8637770897832817</prop>
<tuv xml:lang="en">
<seg>Furthermore, immunisation programmes help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Barra minn hekk, il-programmi tal-immunizzazzjoni jgħinu biex inaqqsu l-piżijiet soċjali, psikoloġiċi u finanzjarji tal-mard fuq in-nies u l-gvernijiet, inaqqsu l-pressjonijiet fuq is-sistemi tal-kura tas-saħħa u tal-kura soċjali u jippermettu lin-nies iwettqu attivitajiet produttivi li jinkludu l-edukazzjoni u l-impjieg.</seg>
</tuv>
</tu>
<tu tuid="31">
<prop type="lengthRatio">0.9504950495049505</prop>
<tuv xml:lang="en">
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-immunità komunitarja sseħħ meta biżżejjed persuni f'popolazzjoni jkunu immuni għal marda infettiva.</seg>
</tuv>
</tu>
<tu tuid="32">
<prop type="lengthRatio">0.8586956521739131</prop>
<tuv xml:lang="en">
<seg>However, people cannot rely on community immunity for some infectious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, in-nies ma jistgħux jiddependu fuq l-immunità komunitarja għal xi mard infettiv.</seg>
</tuv>
</tu>
<tu tuid="33">
<prop type="lengthRatio">0.883495145631068</prop>
<tuv xml:lang="en">
<seg>For example, tetanus can be encountered due to common injuries, including dog or cat bites.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, it-tetnu jista' jittieħed minħabba korrimenti komuni, inkluż gdim tal-klieb jew tal-qtates.</seg>
</tuv>
</tu>
<tu tuid="34">
<prop type="lengthRatio">1.0512820512820513</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for the community</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-benefiċċji tat-tilqim għall-komunità</seg>
</tuv>
</tu>
<tu tuid="35">
<prop type="lengthRatio">1.054054054054054</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for individuals</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Benefiċċji tat-tilqim għall-individwi</seg>
</tuv>
</tu>
<tu tuid="36">
<prop type="lengthRatio">0.8988095238095238</prop>
<tuv xml:lang="en">
<seg>These include babies, children, the elderly, people with weak immune systems, cancer patients, and people who cannot be vaccinated for medical reasons.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jinkludu t-trabi, it-tfal, l-anzjani, il-persuni b'sistemi immunitarja dgħajfa, pazjenti bil-kanċer, u persuni li ma jistgħux jitlaqqmu minħabba raġunijiet mediċi.</seg>
</tuv>
</tu>
<tu tuid="37">
<prop type="lengthRatio">0.75</prop>
<tuv xml:lang="en">
<seg>In this way, vaccines indirectly protect others who are vulnerable to disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'dan il-mod, il-vaċċini b'mod indirett jipproteġu lill-persuni l-oħra li jkunu vulnerabbli għall-marda.</seg>
</tuv>
</tu>
<tu tuid="38">
<prop type="lengthRatio">0.8181818181818182</prop>
<tuv xml:lang="en">
<seg>red rash;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>raxx aħmar;</seg>
</tuv>
</tu>
<tu tuid="39">
<prop type="lengthRatio">1.0298507462686568</prop>
<tuv xml:lang="en">
<seg>Up to 50% of people infected with rubella do not experience symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sa 50 % tal-persuni infettati bir-rubella ma jesperjenzawx sintomi.</seg>
</tuv>
</tu>
<tu tuid="40">
<prop type="lengthRatio">0.952</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR (il-ħosba, il-gattone u r-rubella) huwa vaċċin ikkombinat li jipproteġi kontra l-ħosba, il-gattone u r-rubella.</seg>
</tuv>
</tu>
<tu tuid="41">
<prop type="lengthRatio">0.8363636363636363</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-Rubella (il-ħosba Ġermaniża) hija infezzjoni virali.</seg>
</tuv>
</tu>
<tu tuid="42">
<prop type="lengthRatio">1.0952380952380953</prop>
<tuv xml:lang="en">
<seg>pain and inflammation of the joints in adults.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ u infjammazzjoni tal-ġogi fl-adulti.</seg>
</tuv>
</tu>
<tu tuid="43">
<prop type="lengthRatio">1.064516129032258</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tar-rubella?</seg>
</tuv>
</tu>
<tu tuid="44">
<prop type="lengthRatio">0.6341463414634146</prop>
<tuv xml:lang="en">
<seg>Who is at risk of rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu r-rubella?</seg>
</tuv>
</tu>
<tu tuid="45">
<prop type="lengthRatio">0.911504424778761</prop>
<tuv xml:lang="en">
<seg>The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-virus tar-rubella jinfirex minn taqtiriet fl-arja li jiġu prodotti meta l-persuna infettata tisgħol u tagħtas.</seg>
</tuv>
</tu>
<tu tuid="46">
<prop type="lengthRatio">0.9411764705882353</prop>
<tuv xml:lang="en">
<seg>What is rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi r-rubella?</seg>
</tuv>
</tu>
<tu tuid="47">
<prop type="lengthRatio">0.9315068493150684</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective and has very few side effects.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR huwa sikur u effikaċi u ma tantx għandu effetti sekondarji.</seg>
</tuv>
</tu>
<tu tuid="48">
<prop type="lengthRatio">0.9856459330143541</prop>
<tuv xml:lang="en">
<seg>The consequences for unvaccinated pregnant women that get rubella are particularly severe, due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-konsegwenzi għan-nisa tqal li mhumiex imlaqqma li taqbadhom ir-rubella huma partikolarment severi, probabbli minħabba l-fatt li l-marda waqt it-tqala tista' twassal għal korriment jew CRS fit-trabi tagħhom.</seg>
</tuv>
</tu>
<tu tuid="49">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The only protection against rubella is vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-unika protezzjoni kontra r-rubella hija t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="50">
<prop type="lengthRatio">0.7967032967032966</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi reċipjenti tal-vaċċin jiżviluppaw raxx ħafif mhux infettiv li jixbah lill-ħosba, tipikament bejn sebat ijiem u 14-il jum wara t-tilqima, li jisparixxi bejn jum u tlett ijiem wara.</seg>
</tuv>
</tu>
<tu tuid="51">
<prop type="lengthRatio">0.9444444444444444</prop>
<tuv xml:lang="en">
<seg>However, if a woman gets rubella during the first three months of pregnancy, it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome (CRS).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, jekk mara taqbadha r-rubella matul l-ewwel tliet xhur tat-tqala, x'aktarx li tirriżulta f'korriment jew f'tarbija li titwieled b'disturbi konġenitali magħrufa bħala sindrome tar-rubella konġenitali (CRS).</seg>
</tuv>
</tu>
<tu tuid="52">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>swollen lymph glands around the ears and the back of the head;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>għoqiedi limfatiċi minfuħa madwar il-widnejn u f'wara tar-ras;</seg>
</tuv>
</tu>
<tu tuid="53">
<prop type="lengthRatio">0.8940397350993378</prop>
<tuv xml:lang="en">
<seg>Women who plan to become pregnant should check their vaccination status, as they cannot be vaccinated against rubella during pregnancy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>In-nisa li beħsiebhom joħorġu tqal għandhom jivverifikaw l-istatus ta' tilqim tagħhom, peress li ma jistgħux jitlaqqmu kontra r-rubella matul it-tqala.</seg>
</tuv>
</tu>
<tu tuid="54">
<prop type="lengthRatio">0.9122807017543859</prop>
<tuv xml:lang="en">
<seg>In healthy individuals it is usually a mild disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'individwi b'saħħithom din normalment tkun marda ħafifa.</seg>
</tuv>
</tu>
<tu tuid="55">
<prop type="lengthRatio">1.0521739130434782</prop>
<tuv xml:lang="en">
<seg>Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull min għadha ma qabditux il-marda jew min ma kienx imlaqqam bil-vaċċin MMR qiegħed f'riskju li taqbdu r-rubella.</seg>
</tuv>
</tu>
<tu tuid="56">
<prop type="lengthRatio">1.4074074074074074</prop>
<tuv xml:lang="en">
<seg>What are the complications of rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi kkurata r-rubella?</seg>
</tuv>
</tu>
<tu tuid="57">
<prop type="lengthRatio">0.8409090909090909</prop>
<tuv xml:lang="en">
<seg>CRS can lead to deafness, cataracts and learning disabilities in the baby.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-CRS tista' twassal għal truxija, katarretti u diżabilitajiet fit-tagħlim fit-tarbija.</seg>
</tuv>
</tu>
<tu tuid="58">
<prop type="lengthRatio">1.0277777777777777</prop>
<tuv xml:lang="en">
<seg>When symptoms do occur, they include:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta s-sintomi jidhru, dawn jikludu:</seg>
</tuv>
</tu>
<tu tuid="59">
<prop type="lengthRatio">0.9672131147540983</prop>
<tuv xml:lang="en">
<seg>Two doses of the vaccine are needed for maximum protection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-protezzjoni massima huma meħtieġa żewġ dożi tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="60">
<prop type="lengthRatio">0.6216216216216216</prop>
<tuv xml:lang="en">
<seg>How is rubella treated?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta r-rubella?</seg>
</tuv>
</tu>
<tu tuid="61">
<prop type="lengthRatio">0.8297872340425532</prop>
<tuv xml:lang="en">
<seg>European Vaccination Information Portal</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Portal Ewropew ta 'Informazzjoni dwar it-Tilqim</seg>
</tuv>
</tu>
<tu tuid="62">
<prop type="lengthRatio">0.9375</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-Ewropa, l-influwenza sseħħ...</seg>
</tuv>
</tu>
<tu tuid="63">
<prop type="lengthRatio">0.9696969696969697</prop>
<tuv xml:lang="en">
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-influwenza hija marda respiratorja li tittieħed ikkawżata minn infezzjoni b'virus tal-influwenza.</seg>
</tuv>
</tu>
<tu tuid="64">
<prop type="lengthRatio">1.0252100840336134</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull virus u batterju joħloq reazzjoni unika fis-sistema immunitarja li tinvolvi sett speċifiku ta' ċelloli fid-demm...</seg>
</tuv>
</tu>
<tu tuid="65">
<prop type="lengthRatio">1.0333333333333334</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-individwi kontra mard li jista' jkollu konsegwenzi serji għal...</seg>
</tuv>
</tu>
<tu tuid="66">
<prop type="lengthRatio">2.0727272727272728</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rubella (il-ħosba Ġermaniża) hija infezzjoni virali.</seg>
</tuv>
</tu>
<tu tuid="67">
<prop type="lengthRatio">1.10752688172043</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-persuni mlaqqma u lill-persuni ta' madwarhom li huma vulnerabbli...</seg>
</tuv>
</tu>
<tu tuid="68">
<prop type="lengthRatio">1.2142857142857142</prop>
<tuv xml:lang="en">
<seg>When to vaccinate</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tagħbija aktar</seg>
</tuv>
</tu>
<tu tuid="69">
<prop type="lengthRatio">0.8615384615384616</prop>
<tuv xml:lang="en">
<seg>Vaccines protect people during different stages of life.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini jipproteġu lin-nies matul stadji differenti tal-ħajja.</seg>
</tuv>
</tu>
<tu tuid="70">
<prop type="lengthRatio">0.6818181818181818</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini huma rakkomandati għal gruppi ta' etajiet differenti...</seg>
</tuv>
</tu>
<tu tuid="71">
<prop type="lengthRatio">0.9333333333333333</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel ma vaċċin ikun jista' jiġi approvat fl-UE, irid jgħaddi minn ittestjar rigoruż mill-iżviluppatur...</seg>
</tuv>
</tu>
<tu tuid="72">
<prop type="lengthRatio">1.5</prop>
<tuv xml:lang="en">
<seg>Trusted sources</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aqra iktar</seg>
</tuv>
</tu>
<tu tuid="73">
<prop type="lengthRatio">0.994413407821229</prop>
<tuv xml:lang="en">
<seg>It also provides an overview of the mechanisms in place in the European Union (EU) to ensure that available vaccines conform to the highest standards of safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jipprovdi wkoll ħarsa ġenerali lejn il-mekkaniżmi implimentati fl-Unjoni Ewropea (UE) biex jiġi żgurat li l-vaċċini jikkonformaw mal-ogħla standards ta' sigurtà u effettività.</seg>
</tuv>
</tu>
<tu tuid="74">
<prop type="lengthRatio">1.1505376344086022</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis hija marda batterika infettiva ħafna li tinvolvi l-pulmun u l-passaġġi tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="75">
<prop type="lengthRatio">0.9666666666666667</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskop ewlieni ta' dan is-sit web huwa li jipprovdi evidenza preċiża, oġġettiva u aġġornata dwar il-vaċċini u t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="76">
<prop type="lengthRatio">2.2280701754385963</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination in general.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'individwi b'saħħithom din normalment tkun marda ħafifa.</seg>
</tuv>
</tu>
<tu tuid="77">
<prop type="lengthRatio">1.3411764705882352</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni hija maqsuma f'dipartimenti li jiżviluppaw politiki f'oqsma speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="78">
<prop type="lengthRatio">0.9767441860465116</prop>
<tuv xml:lang="en">
<seg>Approval of vaccines in the European Union</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="79">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Safety, quality and standards</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sikurezza, kwalità ustandards</seg>
</tuv>
</tu>
<tu tuid="80">
<prop type="lengthRatio">0.8536585365853658</prop>
<tuv xml:lang="en">
<seg>Serious side effects are very rare.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Effetti sekondarji serji huma rari ħafna.</seg>
</tuv>
</tu>
<tu tuid="81">
<prop type="lengthRatio">0.9230769230769231</prop>
<tuv xml:lang="en">
<seg>The last known naturally occurring case was recorded in 1977 in Somalia.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-aħħar każ magħruf li seħħ b'mod naturali ġie rreġistrat fl-1977 fis-Somalja.</seg>
</tuv>
</tu>
<tu tuid="82">
<prop type="lengthRatio">0.9221556886227545</prop>
<tuv xml:lang="en">
<seg>Recently, a vaccine was developed against Ebola virus disease, and research is underway on vaccines to protect against human immunodeficiency virus (HIV).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan l-aħħar, ġiet żviluppata tilqima kontra l-virus tal-marda tal-Ebola, u qed issir riċerka dwar tilqim li jipproteġu kontra l-virus tal-immunodefiċjenza umana (HIV).</seg>
</tuv>
</tu>
<tu tuid="83">
<prop type="lengthRatio">1.55</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fatti dwar it-tilqim</seg>
</tuv>
</tu>
<tu tuid="84">
<prop type="lengthRatio">0.920704845814978</prop>
<tuv xml:lang="en">
<seg>The vaccine can only be approved for use in the European Union (EU) and European Economic Area (EEA) after a scientific evaluation of the results of these tests to ensure its quality, safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqima tista' tiġi approvata biss għall-użu fl-Unjoni Ewropea (UE) u ż-Żona Ekonomika Ewropea (ŻEE) wara evalwazzjoni xjentifika tar-riżultati ta' dawn it-testijiet biex tiżgura l-kwalità, is-sikurezza u l-effikaċja tagħha.</seg>
</tuv>
</tu>
<tu tuid="85">
<prop type="lengthRatio">0.9477611940298507</prop>
<tuv xml:lang="en">
<seg>Vaccines work by ‘teaching' a person's immune system (the body's natural defences) to defend itself against a specific disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jaħdem billi ‘jgħallem' lis-sistema immunitarja (id-difiżi naturali tal-ġisem) biex tiddefendi ruħha kontra marda speċifika.</seg>
</tuv>
</tu>
<tu tuid="86">
<prop type="lengthRatio">0.8125</prop>
<tuv xml:lang="en">
<seg>The vaccine is continuously monitored to ensure it remains safe and effective.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqima tkun qed tiġi ssorveljata kontinwament biex jiġi żgurat li tibqa' sikura u effettiva.</seg>
</tuv>
</tu>
<tu tuid="87">
<prop type="lengthRatio">1.2333333333333334</prop>
<tuv xml:lang="en">
<seg>The first vaccine was developed in the 18th century in the United Kingdom.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ewwel tilqima ġiet żviluppata fis-seklu 18 fir-Renju Unit.</seg>
</tuv>
</tu>
<tu tuid="88">
<prop type="lengthRatio">0.9054054054054054</prop>
<tuv xml:lang="en">
<seg>This evaluation needs to show that a vaccine's benefits in protecting people against diseases are far greater than any potential risk.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din l-evalwazzjoni teħtieġ turi li l-benefiċċji tat-tilqima fil-protezzjoni tan-nies kontra l-mard humaħafna akbar minn kwalunkwe riskju potenzjali.</seg>
</tuv>
</tu>
<tu tuid="89">
<prop type="lengthRatio">0.9193548387096774</prop>
<tuv xml:lang="en">
<seg>The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully, in particular because vaccines are given to healthy people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-esperti xjentifiċi li jevalwaw it-tilqim dejjem iqisu l-benefiċċji u kwalunkwe riskju potenzjali b'attenzjoni kbira, b'mod partikolari minħabba tilqim li jingħata lil nies f'saħħithom.</seg>
</tuv>
</tu>
<tu tuid="90">
<prop type="lengthRatio">0.8581560283687943</prop>
<tuv xml:lang="en">
<seg>As with any medicine, some people may experience side effects from a vaccine, but these are usually mild and short-lived.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Bħal kull mediċina oħra, xi wħud min-nies jistgħu jesperjenzaw effetti sekondarji mit-tilqima, iżda dawn ikunu ġeneralment ħfief u ma jdumux.</seg>
</tuv>
</tu>
<tu tuid="91">
<prop type="lengthRatio">0.7642276422764228</prop>
<tuv xml:lang="en">
<seg>Only then, after approval, can a vaccine be manufactured, marketed and used to protect people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'hekk biss, wara l-approvazzjoni, tista' tilqima tiġimanifatturata, titqiegħed fis-suq u tintuża biex tipproteġi lin-nies.</seg>
</tuv>
</tu>
<tu tuid="92">
<prop type="lengthRatio">0.8414634146341463</prop>
<tuv xml:lang="en">
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel kwalunkwe tilqima ġdida tkun tista' tintuża, irid isirilha ttestjar rigoruż.</seg>
</tuv>
</tu>
<tu tuid="93">
<prop type="lengthRatio">0.7878787878787878</prop>
<tuv xml:lang="en">
<seg>It was a vaccine against smallpox, a deadly disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa jimmira l-aktar lejn mard ikkawżat minn viruses jew batterji.</seg>
</tuv>
</tu>
<tu tuid="94">
<prop type="lengthRatio">0.8333333333333334</prop>
<tuv xml:lang="en">
<seg>They can include mild fever, or pain or redness at the injection site.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ġidri, illum il-ġurnatanqerdet mid-dinja kollha fil-bnedmin bis-saħħa tat-tilqim.</seg>
</tuv>
</tu>
<tu tuid="95">
<prop type="lengthRatio">1.064516129032258</prop>
<tuv xml:lang="en">
<seg>They also help to prevent the spread of diseases in the community.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jgħin ukoll fil-prevenzjoni għat-tixrid tal-mard fil-komunità.</seg>
</tuv>
</tu>
<tu tuid="96">
<prop type="lengthRatio">0.7718120805369127</prop>
<tuv xml:lang="en">
<seg>vaccinating against humanpapilloma virus (HPV) can help prevent cervical and other cancers caused by HPV infection;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tilqim kontra l-virus tal-papilloma umana (HPV) jista' jgħin biex jipprevjeni kanċer ċervikali u kanċers oħrajn ikkawżati mill-infezzjoni tal-HPV;</seg>
</tuv>
</tu>
<tu tuid="97">
<prop type="lengthRatio">0.9937888198757764</prop>
<tuv xml:lang="en">
<seg>The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tikek magħqudin jindikaw in-numru massimu u minimu ta' persuni mhux infettati u mhux imlaqqma preċedentement li jistgħu jiġu infettati minn persuna bil-marda.</seg>
</tuv>
</tu>
<tu tuid="98">
<prop type="lengthRatio">0.8333333333333334</prop>
<tuv xml:lang="en">
<seg>1-4 people</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Influwenza</seg>
</tuv>
</tu>
<tu tuid="99">
<prop type="lengthRatio">0.8064516129032258</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-programmi tat-tilqim għandhom benefiċċji usa' għas-soċjetà.</seg>
</tuv>
</tu>
<tu tuid="100">
<prop type="lengthRatio">0.9122807017543859</prop>
<tuv xml:lang="en">
<seg>vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tilqim kontra l-epatite B jista' jipprevjeni l-kanċer tal-fwied ikkawżat minn infezzjoni tal-epatite B fit-tul.</seg>
</tuv>
</tu>
<tu tuid="101">
<prop type="lengthRatio">0.8661971830985915</prop>
<tuv xml:lang="en">
<seg>This shows both the most conservative estimate (inner ring, darker dots) and the maximum estimate (outer ring, paler dots).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan juri kemm l-aktar stima konservattiva (ċirku ta' ġewwa, tikek aktar skuri) kif ukoll l-istima massima (ċirku ta' barra, tikek aktar ċari).</seg>
</tuv>
</tu>
<tu tuid="102">
<prop type="lengthRatio">0.8884892086330936</prop>
<tuv xml:lang="en">
<seg>They help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jgħinu biex inaqqsu l-piżijiet soċjali, psikoloġiċi u finanzjarji tal-mard fuq in-nies u l-gvernijiet, inaqqsu l-pressjonijiet fuq is-sistemi tal-kura tas-saħħa u tal-kura soċjali u jippermettu lin-nies iwettqu attivitajiet produttivi li jinkludu l-edukazzjoni u l-impjieg.</seg>
</tuv>
</tu>
<tu tuid="103">
<prop type="lengthRatio">1.0476190476190477</prop>
<tuv xml:lang="en">
<seg>Thanks to vaccination:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Bis-saħħa tat-tilqim:</seg>
</tuv>
</tu>
<tu tuid="104">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Vaccination helps prevent the spread of disease in communities.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jgħin jipprevjeni t-tifrix tal-mard fil-komunitajiet.</seg>
</tuv>
</tu>
<tu tuid="105">
<prop type="lengthRatio">1.0092592592592593</prop>
<tuv xml:lang="en">
<seg>Vaccination also prevents the development of certain types of pre-cancerous growths and cancers, for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipprevjeni wkoll l-iżvilupp ta' ċerti tipi ta' tkabbir ta' qabel il-kanċer u kanċers, pereżempju:</seg>
</tuv>
</tu>
<tu tuid="106">
<prop type="lengthRatio">0.9795918367346939</prop>
<tuv xml:lang="en">
<seg>When a large percentage of a population is vaccinated, infectious diseases cannot easily spread.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta perċentwal kbir ta' popolazzjoni jiġi mlaqqam, il-mard infettiv ma jistax jinfirex faċilment.</seg>
</tuv>
</tu>
<tu tuid="107">
<prop type="lengthRatio">0.38823529411764707</prop>
<tuv xml:lang="en">
<seg>Fifth Edition 2008, Elsevier Inc.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tixrid tal-poljo ntemm fil-biċċa l-kbira tal-partijiet tad-dinja, inkluż l-Ewropa.</seg>
</tuv>
</tu>
<tu tuid="108">
<prop type="lengthRatio">0.8222222222222222</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-ġidri r-riħ issa nqerdet fid-dinja kollha;</seg>
</tuv>
</tu>
<tu tuid="109">
<prop type="lengthRatio">0.9183673469387755</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni iċċekkja s-sit web tal-ECDC https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="110">
<prop type="lengthRatio">0.9306930693069307</prop>
<tuv xml:lang="en">
<seg>Symptoms usually appear 7 to 10 days after infection, but may also appear up to 21 days later:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sintomi normalment jidhru 7 sa 10 ijiem wara infezzjoni, iżda jistgħu jidhru wkoll sa 21 jum wara:</seg>
</tuv>
</tu>
<tu tuid="111">
<prop type="lengthRatio">1.0368421052631578</prop>
<tuv xml:lang="en">
<seg>The vaccine for pertussis is usually given in combination with diphtheria and tetanus vaccination (often in combination also with poliomyelitis, Haemophilus influenzae and hepatitis B vaccination).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin għall-pertussis normalment jingħata flimkien mat-tilqima tad-difterite u tat-tetnu (ħafna drabi flimkien ukoll mat-tilqima tal-poljomijelite, Haemophilus influenzae u l-epatite B).</seg>
</tuv>
</tu>
<tu tuid="112">
<prop type="lengthRatio">0.6511627906976745</prop>
<tuv xml:lang="en">
<seg>Who is at risk of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="113">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>What is pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="114">
<prop type="lengthRatio">0.8159509202453987</prop>
<tuv xml:lang="en">
<seg>In adults and older children, complications include inability to breathe for short periods, broken ribs, rectal prolapse and hernias.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-adulti u fi tfal akbar fl-età, il-kumplikazzjonijiet jinkludu n-nuqqas ta' ħila li jieħdu n-nifs għal perjodi qosra, kustilji miksura, prolassi rettali u ernji.</seg>
</tuv>
</tu>
<tu tuid="115">
<prop type="lengthRatio">0.7857142857142857</prop>
<tuv xml:lang="en">
<seg>The most important way to prevent pertussis is through complete immunisation.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-aktar mod importanti ta' kif tiġi pprevenuta l-pertussis huwa permezz ta' immunizzazzjoni sħiħa.</seg>
</tuv>
</tu>
<tu tuid="116">
<prop type="lengthRatio">0.905982905982906</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Nota: L-informazzjoni li tinsab f'din l-iskeda informattiva hija maħsuba għall-iskop ta' informazzjoni ġenerali u ma għandhiex tintuża bħala sostitut tal-għarfien espert individwali u tal-ġudizzju ta' professjonist tal-kura tas-saħħa.</seg>
</tuv>
</tu>
<tu tuid="117">
<prop type="lengthRatio">0.8983050847457628</prop>
<tuv xml:lang="en">
<seg>Adolescents, adults, or children partially immunised generally have milder or somewhat different symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-adolexxenti, l-adulti jew it-tfal parzjalment immunizzati ġeneralment ikollhom sintomi eħfef jew xi ftit differenti.</seg>
</tuv>
</tu>
<tu tuid="118">
<prop type="lengthRatio">1.1311475409836065</prop>
<tuv xml:lang="en">
<seg>A primary course of 2-3 doses is usually given between two and twelve months of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kors primarju ta' 2-3 dożi normalment jingħata bejn età ta' xahrejn u tnax-il xahar, skont l-iskeda tat-tilqim nazzjonali.</seg>
</tuv>
</tu>
<tu tuid="119">
<prop type="lengthRatio">1.0175438596491229</prop>
<tuv xml:lang="en">
<seg>A third or fourth dose is recommended at 11-24 months of age, and another dose between three and seven years of age.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tielet jew ir-raba' doża hija rakkomandata fl-età ta' 11-24 xahar, u doża oħra bejn età ta' tliet u seba' snin.</seg>
</tuv>
</tu>
<tu tuid="120">
<prop type="lengthRatio">1.0606060606060606</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tal-pertussis?</seg>
</tuv>
</tu>
<tu tuid="121">
<prop type="lengthRatio">1.02</prop>
<tuv xml:lang="en">
<seg>Within two weeks, the cough becomes more severe and is characterized by episodes of numerous rapid coughs, followed by a crowing or high-pitched ‘whoop'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Wara din il-fażi, l-episodji tas-sogħla jsiru inqas frekwenti u inqas severi, u t-tarbija bil-mod teqleb għall-aħjar (dan jista' jieħu sa tliet xhur).</seg>
</tuv>
</tu>
<tu tuid="122">
<prop type="lengthRatio">0.9390243902439024</prop>
<tuv xml:lang="en">
<seg>Some EU/EEA countries recommend boosters for adolescents, adults, and/or women during pregnancy, which also temporarily protects the baby once it is born.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi pajjiżi tal-UE/taż-ŻEE jirrakkomandaw boosters għall-adolexxenti, adulti u/jew nisa waqt it-tqala, li temporanjament, jipproteġu wkoll it-tarbija meta titwieled.</seg>
</tuv>
</tu>
<tu tuid="123">
<prop type="lengthRatio">0.9120879120879121</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din tiġi kkawżata minn batterji fil-ħalq, fl-imnieħer u fil-griżmejn ta' persuna infettata.</seg>
</tuv>
</tu>
<tu tuid="124">
<prop type="lengthRatio">1.32</prop>
<tuv xml:lang="en">
<seg>In young infants the typical 'whoop' may never develop, and the coughing fits may be followed by brief periods when breathing stops.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'dawn il-gruppi, u fi trabi żgħar ħafna, il-pertussis hija aktar diffiċli biex tiġi dijanjostikata.</seg>
</tuv>
</tu>
<tu tuid="125">
<prop type="lengthRatio">1.2903225806451613</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi ttrattata l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="126">
<prop type="lengthRatio">0.9607843137254902</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumplikazzjonijiet jinkludu pulmonite, enċefalopatija (marda tal-moħħ), aċċessjonijiet u anki mewt.</seg>
</tuv>
</tu>
<tu tuid="127">
<prop type="lengthRatio">0.7948717948717948</prop>
<tuv xml:lang="en">
<seg>How can pertussis be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="128">
<prop type="lengthRatio">0.9930555555555556</prop>
<tuv xml:lang="en">
<seg>Pertussis can also be spread by an individual who has only a mild form of the disease, or by an infected individual who has no symptoms at all.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis tista' tinfirex ukoll minn individwu li għandu biss forma ħafifa tal-marda, jew minn individwu infettat li m'għandu l-ebda sintomu.</seg>
</tuv>
</tu>
<tu tuid="129">
<prop type="lengthRatio">0.813953488372093</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din magħrufa wkoll bħala sogħla konvulżiva.</seg>
</tuv>
</tu>
<tu tuid="130">
<prop type="lengthRatio">1.0480769230769231</prop>
<tuv xml:lang="en">
<seg>Initially, symptoms resemble those of a common cold (sneezing, runny nose, low-grade fever and a mild cough).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-bidu, is-sintomi jixbhu dawk ta' riħ komuni (għatis, imnieħer iqattar, deni baxx u sogħla ħafifa).</seg>
</tuv>
</tu>
<tu tuid="131">
<prop type="lengthRatio">0.7623762376237624</prop>
<tuv xml:lang="en">
<seg>It is caused by bacteria in the mouth, nose and throat of an infected person.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis tinfirex minn taqtiriet żgħar fl-arja li jiġu prodotti meta l-persuna infettata tisgħol.</seg>
</tuv>
</tu>
<tu tuid="132">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Some countries also recommend a booster to unprotected women soon after they have delivered, to reduce the risk of transmission of the disease to the baby.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi pajjiżi jirrakkomandaw ukoll booster għal nisa mhux protetti ftit wara li jkunu welldu, biex jitnaqqas ir-riskju ta' trażmissjoni tal-marda lit-tarbija.</seg>
</tuv>
</tu>
<tu tuid="133">
<prop type="lengthRatio">0.9281045751633987</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated with the pertussis vaccine, or whose vaccination status is not up-to-date, is at risk of contracting the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kwalunkwe persuna li mhijiex imlaqqma bil-vaċċin tal-pertussis, jew li l-istatus tat-tilqim tagħha mhuwiex aġġornat, tinsab f'riskju li taqbadha l-marda.</seg>
</tuv>
</tu>
<tu tuid="134">
<prop type="lengthRatio">1.66</prop>
<tuv xml:lang="en">
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-aktar forom severi tal-pertussis huma fit-trabi.</seg>
</tuv>
</tu>
<tu tuid="135">
<prop type="lengthRatio">0.5376344086021505</prop>
<tuv xml:lang="en">
<seg>The most severe forms of pertussis are in infants.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis hija marda batterika infettiva ħafna li tinvolvi l-pulmun u l-passaġġi tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="136">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>the vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tilqima.</seg>
</tuv>
</tu>
<tu tuid="137">
<prop type="lengthRatio">0.9485294117647058</prop>
<tuv xml:lang="en">
<seg>It typically provides lifelong protection and has an effectiveness of around 97-99% among healthy children who receive two doses.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tipikament, din tipprovdi protezzjoni tul il-ħajja u għandha effettività ta' madwar 97-99 % fost tfal b'saħħithom li jirċievu żewġ dożi.</seg>
</tuv>
</tu>
<tu tuid="138">
<prop type="lengthRatio">0.7428571428571429</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety and reporting side effects</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Monitoraġġ tas-sikurezza tal-vaċċin u rappurtar ta' effetti sekondarji</seg>
</tuv>
</tu>
<tu tuid="139">
<prop type="lengthRatio">0.9557522123893806</prop>
<tuv xml:lang="en">
<seg>For example, the vaccine against measles, mumps and rubella (MMR) is highly effective at preventing disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, it-tilqima kontra l-ħosba, il-gattone u r-rubella (MMR) hija effettiva ħafna biex tipprevjeni l-mard.</seg>
</tuv>
</tu>
<tu tuid="140">
<prop type="lengthRatio">0.8725490196078431</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ladarba vaċċin jiġi approvat għall-użu, l-awtoritajiet nazzjonali tal-UE/taż-ŻEE u l-Aġenzija Ewropea għall-Mediċini (EMA), jimmonitorjaw kontinwament l-effetti sekondarji fuq in-nies li rċevew il-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="141">
<prop type="lengthRatio">1.1724137931034482</prop>
<tuv xml:lang="en">
<seg>previous contact with the disease;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kuntatt preċedenti mal-marda;</seg>
</tuv>
</tu>
<tu tuid="142">
<prop type="lengthRatio">0.9416666666666667</prop>
<tuv xml:lang="en">
<seg>Vaccines prevent diseases that could otherwise cause serious health problems, permanent disability or even death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini jipprevjenu mard li kieku seta' jikkawża problemi serji tas-saħħa, diżabilità permanenti jew saħansitra mewt.</seg>
</tuv>
</tu>
<tu tuid="143">
<prop type="lengthRatio">0.991304347826087</prop>
<tuv xml:lang="en">
<seg>Authorised vaccines are effective at preventing disease and protecting the population when administered correctly.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim awtorizzat huwa effettiv biex jipprevjeni l-mard u jipproteġi l-popolazzjoni meta jingħata b'mod korrett.</seg>
</tuv>
</tu>
<tu tuid="144">
<prop type="lengthRatio">1.2916666666666667</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-effettività tat-tilqim</seg>
</tuv>
</tu>
<tu tuid="145">
<prop type="lengthRatio">0.8876404494382022</prop>
<tuv xml:lang="en">
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kapaċità ta' tilqima li tipprevjeni marda speċifika tiddetermina l-effettività tagħha.</seg>
</tuv>
</tu>
<tu tuid="146">
<prop type="lengthRatio">0.8735632183908046</prop>
<tuv xml:lang="en">
<seg>Individual European countries decide which vaccines should be part of their national vaccination programmes and funded by their national health systems.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pajjiżi Ewropej individwali jiddeċiedu liema vaċċini għandhom ikunu parti mill-programmi nazzjonali tat-tilqim tagħhom u ffinanzjati mis-sistemi tas-saħħa nazzjonali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="147">
<prop type="lengthRatio">1.0982142857142858</prop>
<tuv xml:lang="en">
<seg>In some circumstances, a person can still get a disease even after receiving the recommended doses of a vaccine against it.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, f'dawn il-każijiet, is-sintomi tal-persuna ta' spiss ikunu anqas qawwija minn dawk mingħajr tilqima.</seg>
</tuv>
</tu>
<tu tuid="148">
<prop type="lengthRatio">0.8482758620689655</prop>
<tuv xml:lang="en">
<seg>This is due to the person not developing sufficient protection against the disease or due to immunity decreasing over time.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan huwa dovut għall-fatt li l-persuna ma tkunx żviluppat biżżejjed protezzjoni kontra l-marda jew minħabba li l-immunità tibda tonqos maż-żmien.</seg>
</tuv>
</tu>
<tu tuid="149">
<prop type="lengthRatio">0.671875</prop>
<tuv xml:lang="en">
<seg>They are also less likely to infect others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Barra minn hekk, hemm probabbiltà anqas li jinfettaw lil oħrajn.</seg>
</tuv>
</tu>
<tu tuid="150">
<prop type="lengthRatio">1.2647058823529411</prop>
<tuv xml:lang="en">
<seg>other diseases or conditions they may have;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>iż-żmien minn mindu jkunu tlaqqmu;</seg>
</tuv>
</tu>
<tu tuid="151">
<prop type="lengthRatio">1.0508474576271187</prop>
<tuv xml:lang="en">
<seg>Effectiveness in an individual depends on a number of factors.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-effettività f'individwu tiddependi fuq għadd ta' fatturi.</seg>
</tuv>
</tu>
<tu tuid="152">
<prop type="lengthRatio">1.7857142857142858</prop>
<tuv xml:lang="en">
<seg>how the vaccine is given;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>l-età tagħhom;</seg>
</tuv>
</tu>
<tu tuid="153">
<prop type="lengthRatio">1.15</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif jaħdmu l-vaċċini</seg>
</tuv>
</tu>
<tu tuid="154">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>These include:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jinkludu:</seg>
</tuv>
</tu>
<tu tuid="155">
<prop type="lengthRatio">1.6</prop>
<tuv xml:lang="en">
<seg>About us</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħosba</seg>
</tuv>
</tu>
<tu tuid="156">
<prop type="lengthRatio">0.6014492753623188</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-infezzjoni tal-virus tal-papilloma uman (HPV) hija infezzjoni virali li tiġi trażmessa l-aktar sesswalment permezz ta' kuntatt dirett...</seg>
</tuv>
</tu>
<tu tuid="157">
<prop type="lengthRatio">0.41904761904761906</prop>
<tuv xml:lang="en">
<seg>For up-to-date information on COVID-19, see:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel ma vaċċin ikun jista' jiġi approvat fl-UE, irid jgħaddi minn ittestjar rigoruż mill-iżviluppatur...</seg>
</tuv>
</tu>
<tu tuid="158">
<prop type="lengthRatio">0.813953488372093</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="159">
<prop type="lengthRatio">0.2569832402234637</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jipprovdi wkoll ħarsa ġenerali lejn il-mekkaniżmi implimentati fl-Unjoni Ewropea (UE) biex jiġi żgurat li l-vaċċini jikkonformaw mal-ogħla standards ta' sigurtà u effettività.</seg>
</tuv>
</tu>
<tu tuid="160">
<prop type="lengthRatio">0.925</prop>
<tuv xml:lang="en">
<seg>This website does not contain any specific information on the ongoing development of vaccines against COVID-19.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskop ewlieni ta' dan is-sit web huwa li jipprovdi evidenza preċiża, oġġettiva u aġġornata dwar il-vaċċini u t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="161">
<prop type="lengthRatio">1.7</prop>
<tuv xml:lang="en">
<seg>When to vaccinate</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aqra iktar</seg>
</tuv>
</tu>
<tu tuid="162">
<prop type="lengthRatio">0.5480769230769231</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Wieħed mid-dipartimenti huwa d- DĠ għas-Saħħa u s-Sikurezza Alimentari , responsabbli għall-politika tal-UE dwar is-saħħa u s-sikurezza alimentari u biex jimmonitorja l-implimentazzjoni ta' liġijiet relatati.</seg>
</tuv>
</tu>
<tu tuid="163">
<prop type="lengthRatio">0.9292035398230089</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni ċċekkja s-sit web tal-ECDC: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
</tu>
<tu tuid="164">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>Routine HPV vaccination usually takes place between 9 and 14 years of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Normalment, it-tilqim ta' rutina kontra l-HPV isir fl-età ta' bejn 9 u 14-il sena, skont l-iskeda ta' tilqim nazzjonali.</seg>
</tuv>
</tu>
<tu tuid="165">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>genital and anal warts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>felul ġenitali u anali</seg>
</tuv>
</tu>
<tu tuid="166">
<prop type="lengthRatio">1.0240963855421688</prop>
<tuv xml:lang="en">
<seg>The use of condoms is not 100% effective in preventing the transmission of the virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-użu ta' kondoms mhuwiex effettiv 100% fil-prevenzjoni tat-trażmissjoni tal-virus.</seg>
</tuv>
</tu>
<tu tuid="167">
<prop type="lengthRatio">1.0714285714285714</prop>
<tuv xml:lang="en">
<seg>There are more than 100 types of HPV viruses.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hemm aktar minn 100 tip ta' virus ta' HPV.</seg>
</tuv>
</tu>
<tu tuid="168">
<prop type="lengthRatio">0.8461538461538461</prop>
<tuv xml:lang="en">
<seg>Who is at risk of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min huwa f'riskju ta' HPV?</seg>
</tuv>
</tu>
<tu tuid="169">
<prop type="lengthRatio">0.8809523809523809</prop>
<tuv xml:lang="en">
<seg>If HPV does not go away it may cause:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk HPV ma jgħaddix, dan jista' jikkawża:</seg>
</tuv>
</tu>
<tu tuid="170">
<prop type="lengthRatio">0.9230769230769231</prop>
<tuv xml:lang="en">
<seg>Vaccination of girls and boys against HPV can prevent HPV infections and consequently HPV-related diseases in both sexes, including genital and anal warts, cervical cancer and other cancers caused by HPV.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim tal-bniet u tas-subien kontra l-HPV jista' jipprevjeni infezzjonijiet HPV u konsegwentement mard relatat mal-HPV fiż-żewġ sessi, inklużi felul ġenitali u anali, kanċer ċervikali u kanċers oħra kkawżati mill-HPV.</seg>
</tuv>
</tu>
<tu tuid="171">
<prop type="lengthRatio">0.9572649572649573</prop>
<tuv xml:lang="en">
<seg>cervical or other types of cancer (e.g. vulvar, vaginal, anal penile, and some cancers of the head and the neck)</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kanċer ċervikali jew tipi oħra ta' kanċers (eż. vulvari, vaġinali, anali, tal-pene, u xi kanċers tar-ras u tal-għonq)</seg>
</tuv>
</tu>
<tu tuid="172">
<prop type="lengthRatio">0.8607594936708861</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact with an infected person.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-infezzjoni tal-virus tal-papilloma uman (HPV) hija infezzjoni virali li tiġi trażmessa l-aktar sesswalment permezz ta' kuntatt dirett ma' persuna infettata.</seg>
</tuv>
</tu>
<tu tuid="173">
<prop type="lengthRatio">0.7733333333333333</prop>
<tuv xml:lang="en">
<seg>The 'low risk' HPV types can cause genital and anal warts.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tipi ta' HPV ta' "riskju baxx" jistgħu jikkawżaw felul ġenitali u anali.</seg>
</tuv>
</tu>
<tu tuid="174">
<prop type="lengthRatio">0.5</prop>
<tuv xml:lang="en">
<seg>What is HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif jiġi ttrattat l-HPV?</seg>
</tuv>
</tu>
<tu tuid="175">
<prop type="lengthRatio">1.0740740740740742</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi ta' HPV?</seg>
</tuv>
</tu>
<tu tuid="176">
<prop type="lengthRatio">0.8711656441717791</prop>
<tuv xml:lang="en">
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kanċer ċervikali (kanċer tal-għonq tal-utru) huwa l-aktar kanċer komuni wara l-kanċer tas-sider li jaffettwa n-nisa li għandhom bejn 15 u 44 sena fl-Ewropa (1).</seg>
</tuv>
</tu>
<tu tuid="177">
<prop type="lengthRatio">0.8778625954198473</prop>
<tuv xml:lang="en">
<seg>There is no treatment for the virus itself, but the health problems caused by HPV can be treated in different ways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>M'hemm l-ebda trattament għall-virus innifsu, iżda l-problemi tas-saħħa kkawżati mill-HPV jistgħu jiġu ttrattati b'modi differenti.</seg>
</tuv>
</tu>
<tu tuid="178">
<prop type="lengthRatio">0.7769230769230769</prop>
<tuv xml:lang="en">
<seg>At least 14 HPV types, classified as ‘high risk', can cause cancer, such as cervical cancer in women.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tal-inqas 14-il tip ta' HPV, ikklassifikati bħala ta' "riskju għoli", jistgħu jikkawżaw il-kanċer, bħal kanċer ċervikali fin-nisa.</seg>
</tuv>
</tu>
<tu tuid="179">
<prop type="lengthRatio">0.8421052631578947</prop>
<tuv xml:lang="en">
<seg>The ‘high risk' HPV types can also cause anal and genital cancers, and some cancers of the head and neck, in both men and women.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tipi ta' HPV ta' "riskju għoli" jistgħu jikkawżaw ukoll kanċer anali u ġenitali, u xi kanċers tar-ras u tal-għonq, kemm fl-irġiel kif ukoll fin-nisa.</seg>
</tuv>
</tu>
<tu tuid="180">
<prop type="lengthRatio">0.5588235294117647</prop>
<tuv xml:lang="en">
<seg>How is HPV treated?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-HPV, kif tista' tiġi pprevenuta?</seg>
</tuv>
</tu>
<tu tuid="181">
<prop type="lengthRatio">0.7317073170731707</prop>
<tuv xml:lang="en">
<seg>Genital warts can be treated using medication or by surgery.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-felul ġenitali jista' jiġi ttrattat permezz ta' medikazzjoni jew b'operazzjoni.</seg>
</tuv>
</tu>
<tu tuid="182">
<prop type="lengthRatio">0.8613861386138614</prop>
<tuv xml:lang="en">
<seg>A healthcare provider should be consulted for advice on the specific treatment options.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għandu jiġi kkonsultat fornitur tal-kura tas-saħħa għal parir dwar għażliet ta' trattament speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="183">
<prop type="lengthRatio">0.7313432835820896</prop>
<tuv xml:lang="en">
<seg>Cervical cancer and tissue in the cervix that is described as ‘precancerous' can be identified early through cervical cancer screening and treated.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kanċer ċervikali u tessut fl-għonq tal-utru li huwa deskritt bħala "ta' qabel il-kanċer" jistgħu jiġu identifikati fi stadju bikri permezz ta' skrinjar tal-kanċer ċervikali u jistgħu jiġu ttrattati.</seg>
</tuv>
</tu>
<tu tuid="184">
<prop type="lengthRatio">0.7790055248618785</prop>
<tuv xml:lang="en">
<seg>Other HPV-related cancers are also more treatable when diagnosed and treated early, but there are no specific screening programmes for these.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kanċers oħra relatati mal-HPV jistgħu wkoll jiġu ttrattati aktar meta jiġu ddijanjostikati u ttrattati fi stadju kmieni, iżda m'hemm l-ebda programm ta' skrinjar speċifiku għalihom.</seg>
</tuv>
</tu>
<tu tuid="185">
<prop type="lengthRatio">0.9438202247191011</prop>
<tuv xml:lang="en">
<seg>HPV is transmitted by direct contact, mainly sexual, with someone who has the virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-HPV jiġi trażmess b'kuntatt dirett, l-aktar sesswalment, ma' xi ħadd li għandu l-virus.</seg>
</tuv>
</tu>
<tu tuid="186">
<prop type="lengthRatio">0.8823529411764706</prop>
<tuv xml:lang="en">
<seg>Anyone who is sexually active is at risk of contracting HPV.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull min hu sesswalment attiv huwa f'riskju li jiġi infettat bl-HPV.</seg>
</tuv>
</tu>
<tu tuid="187">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>What are the complications of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma l-kumplikazzjoni ta' HPV?</seg>
</tuv>
</tu>
<tu tuid="188">
<prop type="lengthRatio">0.8313253012048193</prop>
<tuv xml:lang="en">
<seg>This is offered to women in accordance with national recommendations.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hija l-aktar infezzjoni li tiġi trażmessa sesswalment b'mod komuni madwar id-dinja.</seg>
</tuv>
</tu>
<tu tuid="189">
<prop type="lengthRatio">0.8148148148148148</prop>
<tuv xml:lang="en">
<seg>The person is also at risk of complications.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-persuna tkun ukoll f'riskju ta' kumplikazzjonijiet.</seg>
</tuv>
</tu>
<tu tuid="190">
<prop type="lengthRatio">1.0677966101694916</prop>
<tuv xml:lang="en">
<seg>Immunity usually lasts for years, and sometimes for a lifetime.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-immunità normalment iddum snin, u xi drabi tul ta' ħajja.</seg>
</tuv>
</tu>
<tu tuid="191">
<prop type="lengthRatio">1.08</prop>
<tuv xml:lang="en">
<seg>This is called the antigen.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jissejjaħ l-antiġene.</seg>
</tuv>
</tu>
<tu tuid="192">
<prop type="lengthRatio">1.0307692307692307</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood, in the bone marrow and all over the body, called T-cells, B-cells, among others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull virus u batterju joħloq reazzjoni unika fis-sistema immunitarja li tinvolvi sett speċifiku ta' ċelloli fid-demm, fil-mudullun u mal-ġisem kollu, imsejħa ċelloli T u ċelloli B, fost l-oħrajn.</seg>
</tuv>
</tu>
<tu tuid="193">
<prop type="lengthRatio">0.918918918918919</prop>
<tuv xml:lang="en">
<seg>Antibodies are special proteins that help kill the infectious agent.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Antikorpi huma proteini speċjali li jgħinu biex jinqatel l-aġent infettiv.</seg>
</tuv>
</tu>
<tu tuid="194">
<prop type="lengthRatio">1.2916666666666667</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-komponenti tal-vaċċin</seg>
</tuv>
</tu>
<tu tuid="195">
<prop type="lengthRatio">1.0625</prop>
<tuv xml:lang="en">
<seg>How vaccines work</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Reazzjoni immuni</seg>
</tuv>
</tu>
<tu tuid="196">
<prop type="lengthRatio">1.0185185185185186</prop>
<tuv xml:lang="en">
<seg>Vaccines contain a greatly weakened or an inactivated (killed) form of a virus or bacterium that usually causes a disease, or a small part of the virus or bacterium.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini fihom forma mdgħajfa ħafna jew inattivata (maqtula) ta' virus jew batterju li normalment jikkawża marda, jew parti żgħira mill-virus jew mill-batterju.</seg>
</tuv>
</tu>
<tu tuid="197">
<prop type="lengthRatio">0.9692307692307692</prop>
<tuv xml:lang="en">
<seg>Later, if the person comes into contact with the actual infectious virus or bacterium, their immune system will ‘remember' it.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar tard, jekk il-persuna tiġi f'kuntatt mal-virus jew mal-batterju infettiv attwali, is-sistema immunitarja tagħhom "tiftakru".</seg>
</tuv>
</tu>
<tu tuid="198">
<prop type="lengthRatio">0.9728260869565217</prop>
<tuv xml:lang="en">
<seg>Immunity through vaccination protects not only the immunised individual but also protects unvaccinated people in the community, such as infants who are too young to be vaccinated.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-immunità permezz tat-tilqim tipproteġi mhux biss lill-individwu immunizzat iżda tipproteġi wkoll lin-nies mhux imlaqqma fil-komunità, bħat-trabi li huma żgħar wisq biex jiġu mlaqqma.</seg>
</tuv>
</tu>
<tu tuid="199">
<prop type="lengthRatio">0.9289940828402367</prop>
<tuv xml:lang="en">
<seg>It will then quickly produce the right antibodies and activate the right immune cells to kill the virus or bacterium, protecting the person from the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din imbagħad tipproduċi malajr l-antikorpi x-xierqa u tattiva ċ-ċelloli immuni x-xierqa biex joqtlu l-virus jew il-batterju, u b'hekk tipproteġi lill-persuna mill-marda.</seg>
</tuv>
</tu>
<tu tuid="200">
<prop type="lengthRatio">1.1018518518518519</prop>
<tuv xml:lang="en">
<seg>A vaccine stimulates an immune response, and a ‘memory' of the body to a specific disease, without causing the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Vaċċin jistimula reazzjoni immuni, u "memorja" tal-ġisem għal marda speċifika, mingħajr ma jikkawża l-marda.</seg>
</tuv>
</tu>
<tu tuid="201">
<prop type="lengthRatio">0.9484536082474226</prop>
<tuv xml:lang="en">
<seg>When a person is given the vaccine, their immune system recognises the antigen as ‘foreign'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta persuna tingħata l-vaċċin, is-sistema immunitarja tagħha tagħraf l-antiġene bħala "barrani".</seg>
</tuv>
</tu>
<tu tuid="202">
<prop type="lengthRatio">0.978494623655914</prop>
<tuv xml:lang="en">
<seg>The immune cells are trained to kill and make antibodies against the disease-causing agent.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Iċ-ċelloli immuni huma mħarrġa joqtlu u joħolqu antikorpi kontra l-aġent li jikkawża l-marda.</seg>
</tuv>
</tu>
<tu tuid="203">
<prop type="lengthRatio">0.891566265060241</prop>
<tuv xml:lang="en">
<seg>This ‘ community immunity ' can only work if enough people are vaccinated.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din l-" immunità komunitarja " tista' taħdem biss jekk jiġu mlaqqma biżżejjed nies.</seg>
</tuv>
</tu>
<tu tuid="204">
<prop type="lengthRatio">0.9747899159663865</prop>
<tuv xml:lang="en">
<seg>In contrast, a person who becomes immune by getting the disease can expose other unvaccinated people to the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'kuntrast għal dan, persuna li ssir immuni billi tieħu l-marda tista' tesponi lil nies oħra mhux imlaqqma għall-marda.</seg>
</tuv>
</tu>
<tu tuid="205">
<prop type="lengthRatio">0.9310344827586207</prop>
<tuv xml:lang="en">
<seg>National governments take account of factors such as their health systems, legal systems and cultural norms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-gvernijiet nazzjonali jikkunsidraw fatturi bħas-sistemi tas-saħħa, is-sistemi legali u n-normi kulturali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="206">
<prop type="lengthRatio">1.0543478260869565</prop>
<tuv xml:lang="en">
<seg>Information on which countries have mandatory vaccination can be found in the Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar liema pajjiżi għandhom tilqim obbligatorju tinsab fl-Aġenda tal-Vaċċini .</seg>
</tuv>
</tu>
<tu tuid="207">
<prop type="lengthRatio">1.0606060606060606</prop>
<tuv xml:lang="en">
<seg>Vaccination schedules in the EU/EEA</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskedi tat-tilqim fl-UE/fiż-ŻEE</seg>
</tuv>
</tu>
<tu tuid="208">
<prop type="lengthRatio">0.972972972972973</prop>
<tuv xml:lang="en">
<seg>Mandatory or recommended vaccination</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tilqim obbligatorju jew irrakkomandat</seg>
</tuv>
</tu>
<tu tuid="209">
<prop type="lengthRatio">0.7469879518072289</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country implements its own immunisation programme.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE jimplimenta l-programm ta' immunizzazzjoni tiegħu stess.</seg>
</tuv>
</tu>
<tu tuid="210">
<prop type="lengthRatio">0.7818181818181819</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country decides if vaccination is mandatory or voluntary in its territory.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE jiddeċiedi jekk it-tilqim huwiex obbligatorju jew volontarju fit-territorju tiegħu.</seg>
</tuv>
</tu>
<tu tuid="211">
<prop type="lengthRatio">0.9221556886227545</prop>
<tuv xml:lang="en">
<seg>In 12 EU/EEA countries, vaccinating children against some diseases is mandatory, although different vaccines are required as mandatory in those countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fi 12-il pajjiż tal-UE/taż-ŻEE, it-tilqim tat-tfal kontra ċertu mard huwa obbligatorju, għalkemm vaċċini differenti huma meħtieġa bħala obbligatorji f'dawn il-pajjiżi.</seg>
</tuv>
</tu>
<tu tuid="212">
<prop type="lengthRatio">0.8809523809523809</prop>
<tuv xml:lang="en">
<seg>EU/EEA countries have achieved high vaccination coverage rates through mandatory and non-mandatory vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pajjiżi tal-UE/taż-ŻEE kisbu rati għoljin ta' kopertura ta' tilqim permezz tat-tilqim obbligatorju u dak mhux obbligatorju.</seg>
</tuv>
</tu>
<tu tuid="213">
<prop type="lengthRatio">0.7875</prop>
<tuv xml:lang="en">
<seg>Most EU/EEA countries offer vaccination on a recommended basis.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-maġġoranza tal-pajjiżi tal-UE/taż-ŻEE joffru t-tilqim fuq bażi rrakkomandata.</seg>
</tuv>
</tu>
<tu tuid="214">
<prop type="lengthRatio">0.8142076502732241</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country is responsible for its own national public health policy, including its national immunisation programme and vaccination schedule.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE huwa responsabbli għall-politika nazzjonali tas-saħħa pubblika tiegħu stess, inkluż il-programm nazzjonali ta' immunizzazzjoni u l-iskeda tat-tilqim tiegħu.</seg>
</tuv>
</tu>
<tu tuid="215">
<prop type="lengthRatio">0.9455128205128205</prop>
<tuv xml:lang="en">
<seg>These may include the age and population to be vaccinated (for example, all children of a certain age or only those in a risk group), the exact type of vaccine (e.g. some ingredients may differ), the number and timing of doses, and whether a vaccine is given alone or in combination with others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jistgħu jinkludu l-età u l-popolazzjoni li għandha tiġi mlaqqma (pereżempju, it-tfal kollha ta' ċerta età jew dawk li jinsabu fi grupp ta' riskju biss), it-tip eżatt tal-vaċċin (eż. xi ingredjenti jistgħu jvarjaw), in-numru u meta jingħataw id-dożi, u jekk il-vaċċin jingħatax waħdu jew flimkien ma' oħrajn.</seg>
</tuv>
</tu>
<tu tuid="216">
<prop type="lengthRatio">0.9888888888888889</prop>
<tuv xml:lang="en">
<seg>Factors driving such differences may include the disease's burden, prevalence of the disease and trends in different countries, the resources and structures of healthcare systems, political and cultural factors, as well as the resilience of the vaccination programme.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fatturi li jixprunaw differenzi bħal dawn jistgħu jinkludu l-piż tal-marda, il-prevalenza tal-marda u x-xejriet f'pajjiżi differenti, ir-riżorsi u l-istrutturi tas-sistemi tal-kura tas-saħħa, fatturi politiċi u kulturali, kif ukoll ir-reżiljenza tal-programm tat-tilqim.</seg>
</tuv>
</tu>
<tu tuid="217">
<prop type="lengthRatio">0.95</prop>
<tuv xml:lang="en">
<seg>Information on the national vaccination schedules in EU/EEA countries can be found in the ECDC Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar l-iskedi tat-tilqim nazzjonali fil-pajjiżi tal-UE/taż-ŻEE tinstab fl-Iskedatur tal-Vaċċini tal-ECDC .</seg>
</tuv>
</tu>
<tu tuid="218">
<prop type="lengthRatio">0.863013698630137</prop>
<tuv xml:lang="en">
<seg>The same level of protection is ensured in each EU/EEA country.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-istess livell ta' protezzjoni jiġi żgurat f'kull pajjiż tal-UE/taż-ŻEE.</seg>
</tuv>
</tu>
<tu tuid="219">
<prop type="lengthRatio">0.9681528662420382</prop>
<tuv xml:lang="en">
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hemm xi differenzi fil-mod ta' kif il-pajjiżi jorganizzaw l-iskedi tat-tilqim tagħhom, li huma simili iżda mhux identiċi f'pajjiżi differenti tal-UE/taż-ŻEE.</seg>
</tuv>
</tu>
<tu tuid="220">
<prop type="lengthRatio">1.010989010989011</prop>
<tuv xml:lang="en">
<seg>The childhood vaccination schedules in all EU/EEA countries include the vaccination against:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskedi tat-tilqim fit-tfulija fil-pajjiżi kollha tal-UE/taż-ŻEE jinkludu t-tilqim kontra:</seg>
</tuv>
</tu>
<tu tuid="221">
<prop type="lengthRatio">0.9594594594594594</prop>
<tuv xml:lang="en">
<seg>They just take into account different circumstances and health systems.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn sempliċiment jikkunsidraw ċirkostanzi u sistemi tas-saħħa differenti.</seg>
</tuv>
</tu>
<tu tuid="222">
<prop type="lengthRatio">1.0714285714285714</prop>
<tuv xml:lang="en">
<seg>Vaccines in the national schedules are given in the appropriate timeframes to ensure adequate protection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini fl-iskedi nazzjonali jingħataw fiż-żminijiet xierqa biex jiżguraw protezzjoni adegwata.</seg>
</tuv>
</tu>
<tu tuid="223">
<prop type="lengthRatio">3.875</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-ħosba</seg>
</tuv>
</tu>
<tu tuid="224">
<prop type="lengthRatio">0.9607843137254902</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/measles/facts/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni ara s-sit web tal-ECDC: https://www.ecdc.europa.eu/en/measles/facts/factsheet</seg>
</tuv>
</tu>
<tu tuid="225">
<prop type="lengthRatio">3.0</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħosba</seg>
</tuv>
</tu>
<tu tuid="226">
<prop type="lengthRatio">0.9852941176470589</prop>
<tuv xml:lang="en">
<seg>on the third to seventh day, the temperature may reach up to 41 ⁰C;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>bejn it-tielet u s-seba' jum, it-temperatura tista' titla' sa 41 ⁰C;</seg>
</tuv>
</tu>
<tu tuid="227">
<prop type="lengthRatio">0.8984375</prop>
<tuv xml:lang="en">
<seg>Symptoms include personality changes, gradual mental deterioration, muscle spasms and other neuromuscular symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sintomi jinkludu tibdiliet fil-personalità, deterjorament mentali gradwali, spażmi tal-muskoli u sintomi newromuskolari oħra.</seg>
</tuv>
</tu>
<tu tuid="228">
<prop type="lengthRatio">0.6666666666666666</prop>
<tuv xml:lang="en">
<seg>Who is at risk of measles?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="229">
<prop type="lengthRatio">0.9315068493150684</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR (il-ħosba, il-gattone u r-rubella) huwa vaċċin ikkombinat li jipproteġi kontra l-ħosba, il-gattone u r-rubella (il-ħosba Ġermaniża).</seg>
</tuv>
</tu>
<tu tuid="230">
<prop type="lengthRatio">0.8493150684931506</prop>
<tuv xml:lang="en">
<seg>Measles symptoms usually appear after 10-12 days of infection:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sintomi tal-ħosba normalment jidhru wara 10-12-il jum mill-infezzjoni:</seg>
</tuv>
</tu>
<tu tuid="231">
<prop type="lengthRatio">0.8881118881118881</prop>
<tuv xml:lang="en">
<seg>Very rarely, a persistent measles virus infection can produce subacute sclerosing panencephalitis (SSPE), a disease in which nerves and brain tissue degenerate progressively and which is more likely to appear if measles infection occurs at a younger age.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'każijiet rarissimi, infezzjoni persistenti bil-virus tal-ħosba tista' tipproduċi panenċefalite sklerożanti subakuta (SSPE), marda li fiha n-nervi u t-tessut tal-moħħ jiddeġeneraw b'mod progressiv u li għandha probabbiltà akbar li tidher jekk l-infezzjoni bil-ħosba sseħħ f'età iżgħar.</seg>
</tuv>
</tu>
<tu tuid="232">
<prop type="lengthRatio">0.8823529411764706</prop>
<tuv xml:lang="en">
<seg>30% of children and adults infected with measles can develop complications.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>30% tat-tfal u tal-adulti infettati bil-ħosba jistgħu jiżviluppaw kumplikazzjonijiet.</seg>
</tuv>
</tu>
<tu tuid="233">
<prop type="lengthRatio">0.9177489177489178</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Nota: L-informazzjoni li tinsab f'din l-iskeda informattiva hija maħsuba għall-iskop ta' informazzjoni ġenerali u ma għandhiex tintuża bħala sostitut tal-għarfien espert individwali u tal-ġudizzju ta' professjonist fil-kura medika.</seg>
</tuv>
</tu>
<tu tuid="234">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>It is estimated that one person with measles can infect on average between 12 and 18 unprotected people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa stmat li persuna waħda bil-ħosba tista' tinfetta bħala medja bejn 12 u 18-il persuna mhux protetta.</seg>
</tuv>
</tu>
<tu tuid="235">
<prop type="lengthRatio">0.9871794871794872</prop>
<tuv xml:lang="en">
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rata ta' mortalità għall-ħosba hija ta' persuna sa tlieta għal kull 1 000 każ u l-ogħla f'dawk iżgħar minn ħames snin u fost individwi immunokompromessi.</seg>
</tuv>
</tu>
<tu tuid="236">
<prop type="lengthRatio">0.9279279279279279</prop>
<tuv xml:lang="en">
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-virus tal-ħosba jinfirex minn taqtiriet fl-arja li jiġu prodotti meta l-persuna infettata tisgħol u tagħtas.</seg>
</tuv>
</tu>
<tu tuid="237">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>Measles spreads easily among unvaccinated individuals.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ħosba tinfirex faċilment fost individwi mhux imlaqqma.</seg>
</tuv>
</tu>
<tu tuid="238">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>A person who is infected may transmit measles even before the rash appears (usually 4 days), and for about 4 days after the rash has appeared.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Persuna infettata tista' tittrażmetti l-ħosba anki qabel ma jidher ir-raxx (normalment 4 ijiem), u għal madwar 4 ijiem wara li jidher ir-raxx.</seg>
</tuv>
</tu>
<tu tuid="239">
<prop type="lengthRatio">0.8285714285714286</prop>
<tuv xml:lang="en">
<seg>How can measles be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="240">
<prop type="lengthRatio">0.9047619047619048</prop>
<tuv xml:lang="en">
<seg>SSPE typically appears several years after the affected patient had measles; on average it is seen 7 to 10 years after the infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-SSPE tipikament tidher wara bosta snin wara li l-pazjent affettwat ikollu l-ħosba; bħala medja, tiġi osservata wara 7 sa 10 snin mill-infezzjoni.</seg>
</tuv>
</tu>
<tu tuid="241">
<prop type="lengthRatio">0.912621359223301</prop>
<tuv xml:lang="en">
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madwar pazjent wieħed bil-ħosba minn 1 000 jiżviluppa infjammazzjoni tat-tessut tal-moħħ (enċefalite), kundizzjoni li twassal għal diżabilità newroloġika permanenti f'madwar wieħed minn kull erba' każijiet.</seg>
</tuv>
</tu>
<tu tuid="242">
<prop type="lengthRatio">0.972972972972973</prop>
<tuv xml:lang="en">
<seg>Virus-containing droplets can remain in the air for several hours and the virus remains infectious on contaminated surfaces for up to two hours.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Taqtiriet li jkun fihom il-virus jistgħu jibqgħu fl-arja għal diversi sigħat u l-virus jibqa' infettiv fuq uċuħ kontaminati sa massimu ta' sagħtejn.</seg>
</tuv>
</tu>
<tu tuid="243">
<prop type="lengthRatio">0.9629629629629629</prop>
<tuv xml:lang="en">
<seg>Antibiotics are not effective against measles because it is caused by a virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-antibijotiċi mhumiex effettivi kontra l-ħosba għaliex hija kkawżata minn virus.</seg>
</tuv>
</tu>
<tu tuid="244">
<prop type="lengthRatio">0.9836065573770492</prop>
<tuv xml:lang="en">
<seg>Pneumonia is the most common cause of measles-related death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-protezzjoni massima huma meħtieġa żewġ dożi tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="245">
<prop type="lengthRatio">1.21875</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħafna nies jirkupraw b'kura ta' sostenn, li tista' tinkludi idrazzjoni u mediċini kontra d-deni.</seg>
</tuv>
</tu>
<tu tuid="246">
<prop type="lengthRatio">1.1379310344827587</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of measles?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tal-ħosba?</seg>
</tuv>
</tu>
<tu tuid="247">
<prop type="lengthRatio">0.8324607329842932</prop>
<tuv xml:lang="en">
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, l-antibijotiċi spiss jintużaw sabiex jikkuraw kumplikazzjonijiet b'infezzjonijiet batterjali li jistgħu jiżviluppaw minħabba l-ħosba, bħall-pulmonite u infezzjonijiet tal-widnejn.</seg>
</tuv>
</tu>
<tu tuid="248">
<prop type="lengthRatio">0.7563451776649747</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7 - 14 days after vaccination, which disappears within 1 - 3 days.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi wħud minn dawk li jingħataw il-vaċċin jiżviluppaw raxx ħafif mhux infettiv li jixbah lill-ħosba, tipikament bejn sebat ijiem u 14-il jum wara t-tilqim, li jisparixxi bejn jum u tlett ijiem wara.</seg>
</tuv>
</tu>
<tu tuid="249">
<prop type="lengthRatio">1.0408163265306123</prop>
<tuv xml:lang="en">
<seg>The only protection against measles is vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-unika protezzjoni kontra l-ħosba hija t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="250">
<prop type="lengthRatio">0.7966101694915254</prop>
<tuv xml:lang="en">
<seg>These can include ear infections and diarrhoea.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jistgħu jinkludu infezzjonijiet tal-widnejn u dijarea.</seg>
</tuv>
</tu>
<tu tuid="251">
<prop type="lengthRatio">0.981651376146789</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ħosba hija marda virali kuntaġġuża ħafna li tista' tittieħed fi kwalunkwe età, u li tista' tinfirex ħafna.</seg>
</tuv>
</tu>
<tu tuid="252">
<prop type="lengthRatio">1.2222222222222223</prop>
<tuv xml:lang="en">
<seg>There is no cure for SSPE and it always leads to death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ma teżisti l-ebda kura speċifika għall-ħosba.</seg>
</tuv>
</tu>
<tu tuid="253">
<prop type="lengthRatio">1.6304347826086956</prop>
<tuv xml:lang="en">
<seg>initial symptoms resemble a cold with a runny nose, cough and a mild fever;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>l-għajnejn isiru ħomor u sensittivi għad-dawl;</seg>
</tuv>
</tu>
<tu tuid="254">
<prop type="lengthRatio">1.25</prop>
<tuv xml:lang="en">
<seg>a red rash lasting four to seven days begins on the face and then spreads over the entire body;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>jistgħu jidhru wkoll ponot bojod żgħar fuq il-ħanek u fuq ġewwa tal-ħaddejn.</seg>
</tuv>
</tu>
<tu tuid="255">
<prop type="lengthRatio">1.0508474576271187</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine may be given earlier in life during outbreaks.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR tista' tingħata aktar kmieni matul tifqigħat.</seg>
</tuv>
</tu>
<tu tuid="256">
<prop type="lengthRatio">0.9032258064516129</prop>
<tuv xml:lang="en">
<seg>Vaccination against pertussis is part of national immunisation programmes in the EU.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tlaqqim kontra l-pertussis huwa parti minn programmi nazzjonali ta' immunizzazzjoni fl-UE.</seg>
</tuv>
</tu>
<tu tuid="257">
<prop type="lengthRatio">1.0127659574468084</prop>
<tuv xml:lang="en">
<seg>For example, during 2018 about 86% of infants worldwide received three doses of the vaccine that protects them against diphtheria, tetanus and pertussis (DTP), and 85% of infants around the world received three doses of polio vaccine (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, matul l-2018 madwar 86 % tat-trabi madwar id-dinja rċevew tliet dożi tal-vaċċin li jipproteġihom mid-difterite, it-tetnu u l-pertussis (DTP), u 85 % tat-trabi madwar id-dinja rċevew tliet dożi tal-vaċċin kontra l-poljo (1).</seg>
</tuv>
</tu>
<tu tuid="258">
<prop type="lengthRatio">1.0555555555555556</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR huwa sikur u effettiv.</seg>
</tuv>
</tu>
<tu tuid="259">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>This protects children from whooping cough, while it only causes minor side effects.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jipproteġi lit-tfal mis-sogħla konvulżiva, filwaqt li jikkawża biss effetti sekondarji minuri.</seg>
</tuv>
</tu>
<tu tuid="260">
<prop type="lengthRatio">0.9058823529411765</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR jipproteġi kontra l-ħosba, il-gattone u r-rubella (il-ħosba Ġermaniża).</seg>
</tuv>
</tu>
<tu tuid="261">
<prop type="lengthRatio">0.90625</prop>
<tuv xml:lang="en">
<seg>Less than 5% will have fever.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Inqas minn 5 % ikollhom id-deni.</seg>
</tuv>
</tu>
<tu tuid="262">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>It will often lead to hospitalisation in infants, and the risk of complications and hospitalisation increases for infants younger than three months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ta' spiss twassal għal ospitalizzazzjoni fit-trabi, u r-riskju ta' komplikazzjonijiet u ospitalizzazzjoni jiżdied għal trabi iżgħar minn tliet xhur.</seg>
</tuv>
</tu>
<tu tuid="263">
<prop type="lengthRatio">0.6619718309859155</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara l-iskeda informattiva dwar il-pertussis .</seg>
</tuv>
</tu>
<tu tuid="264">
<prop type="lengthRatio">0.9272727272727272</prop>
<tuv xml:lang="en">
<seg>Complications can include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-komplikazzjonijiet jistgħu jinkludu pulmonite, enċefalopatija (marda tal-moħħ), aċċessjonijiet u anki mewt.</seg>
</tuv>
</tu>
<tu tuid="265">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>About 20% of infants will have redness and pain at the injection site.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madwar 20 % tat-trabi jkollhom ħmurija u wġigħ fis-sit tal-injezzjoni.</seg>
</tuv>
</tu>
<tu tuid="266">
<prop type="lengthRatio">1.0718954248366013</prop>
<tuv xml:lang="en">
<seg>However, since October 2016 a resurgence of measles has been observed in the EU/EEA, with outbreaks in several countries (2), due to a decline in vaccination rates.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, minn Ottubru 2016 ġie osservat ritorn ġdid tal-ħosba fl-UE/fiż-ŻEE, b'tifqigħat f'diversi pajjiżi (2), minħabba tnaqqis fir-rati tat-tlaqqim.</seg>
</tuv>
</tu>
<tu tuid="267">
<prop type="lengthRatio">1.2777777777777777</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Eżempju: pertussis</seg>
</tuv>
</tu>
<tu tuid="268">
<prop type="lengthRatio">0.8488372093023255</prop>
<tuv xml:lang="en">
<seg>It can cause severe spasms of cough and usually lasts three to six weeks.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tista' tikkawża spażmi severi ta' sogħla u normalment iddum bejn tliet u sitt ġimgħat.</seg>
</tuv>
</tu>
<tu tuid="269">
<prop type="lengthRatio">0.7654320987654321</prop>
<tuv xml:lang="en">
<seg>Pertussis (whooping cough) is a disease affecting the airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis (is-sogħla konvulżiva) hija marda li taffettwa l-pajpijiet tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="270">
<prop type="lengthRatio">0.5625</prop>
<tuv xml:lang="en">
<seg>For more information, see measles factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għaldaqstant, il-benefiċċji fit-tul tat-tilqim jaf ma jkunux evidenti mal-ewwel.</seg>
</tuv>
</tu>
<tu tuid="271">
<prop type="lengthRatio">0.831081081081081</prop>
<tuv xml:lang="en">
<seg>Unlike a treatment given to cure an illness, vaccines are usually given to healthy people to prevent them from getting ill.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'mod differenti għal kura li tingħata biex tikkura marda, il-vaċċini normalment jingħataw lill-persuni b'saħħithom bħala prevenzjoni kontra l-mard.</seg>
</tuv>
</tu>
<tu tuid="272">
<prop type="lengthRatio">1.0072463768115942</prop>
<tuv xml:lang="en">
<seg>Many infectious diseases are very rare today thanks to vaccination, so the negative consequences of these diseases are sometimes forgotten.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħafna mard infettiv huwa rari ħafna illum il-ġurnata grazzi għat-tilqim, allura xi drabi l-konsegwenzi negattivi ta' dan il-mard jintesew.</seg>
</tuv>
</tu>
<tu tuid="273">
<prop type="lengthRatio">0.9690721649484536</prop>
<tuv xml:lang="en">
<seg>If people stopped being vaccinated, many of these diseases and related outbreaks could return.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk in-nies jieqfu jitlaqqmu, ħafna minn dan il-mard u t-tifqigħat relatati jistgħu jirritornaw.</seg>
</tuv>
</tu>
<tu tuid="274">
<prop type="lengthRatio">0.9130434782608695</prop>
<tuv xml:lang="en">
<seg>Vaccines are used in hundreds of millions of people worldwide each year to protect from serious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini jintużaw kull sena fuq mijiet ta' miljuni ta' persuni madwar id-dinja biex jipproteġu kontra mard serju.</seg>
</tuv>
</tu>
<tu tuid="275">
<prop type="lengthRatio">0.9151515151515152</prop>
<tuv xml:lang="en">
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Atlas tal-ECDC għas-Sorveljanza tal-Mard Infettiv jipprovdi wkoll data dwar mard ieħor li jista' jiġi evitat bil-vaċċini, bħad-difterite, il-pertussis u r-rubella.</seg>
</tuv>
</tu>
<tu tuid="276">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>Situation of measles in the EU</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sitwazzjoni tal-ħosba fl-UE</seg>
</tuv>
</tu>
<tu tuid="277">
<prop type="lengthRatio">0.8285714285714286</prop>
<tuv xml:lang="en">
<seg>The data is based on information submitted and verified by Member States through ECDC's disease surveillance system.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Id-data hija bbażata fuq l-informazzjoni sottomessa u vverifikata mill-Istati Membri permezz tas-sistema tal-ECDC għas-sorveljanza tal-mard.</seg>
</tuv>
</tu>
<tu tuid="278">
<prop type="lengthRatio">0.7983870967741935</prop>
<tuv xml:lang="en">
<seg>It provides options for the user to filter information by criteria such as disease and time-period.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jipprovdi għażliet sabiex l-utent ikun jista' jiffiltra l-informazzjoni skont il-kriterji bħall-marda u l-perjodu ta' żmien.</seg>
</tuv>
</tu>
<tu tuid="279">
<prop type="lengthRatio">1.1785714285714286</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination and boosters</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tilqim ta' rkupru u boosters</seg>
</tuv>
</tu>
<tu tuid="280">
<prop type="lengthRatio">1.0683229813664596</prop>
<tuv xml:lang="en">
<seg>If a person does not know if they have been vaccinated against a certain disease they can usually get an extra dose without increasing the risk of serious side effects (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk persuna ma tkunx taf jekk ġietx imlaqqma kontra ċerta marda, normalment tista' tieħu doża żejda mingħajr ma żżid ir-riskju ta' effetti sekondarji serji (1).</seg>
</tuv>
</tu>
<tu tuid="281">
<prop type="lengthRatio">0.8896551724137931</prop>
<tuv xml:lang="en">
<seg>For some diseases, such as varicella (chickenpox) and rubella, it is also possible to do a test to check if the person is immune.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal xi mard, bħall-variċella (il-ġidri r-riħ) u r-rubella, huwa wkoll possibbli li jsir test biex jiġi vverifikat jekk il-persuna hijiex immuni.</seg>
</tuv>
</tu>
<tu tuid="282">
<prop type="lengthRatio">0.90625</prop>
<tuv xml:lang="en">
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi pajjiżi jirrakkomandaw dożi booster f'intervalli regolari matul l-adoloxxenza u l-perjodu meta wieħed ikun adult, sabiex tinżamm l-immunità matul perjodu itwal ta' żmien, pereżempju kontra:</seg>
</tuv>
</tu>
<tu tuid="283">
<prop type="lengthRatio">0.7843137254901961</prop>
<tuv xml:lang="en">
<seg>Most vaccines provide lifelong immunity.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħafna mill-vaċċini jipprovdu immunità tul il-ħajja.</seg>
</tuv>
</tu>
<tu tuid="284">
<prop type="lengthRatio">0.9716312056737588</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, minħabba n-numru li qed jiżdied ta' każijiet ta' ħosba fost l-adolexxenti u l-adulti żgħar, jeżistu programmi ta' rkupru f'numru ta' pajjiżi tal-UE/taż-ŻEE għal persuni li setgħu tilfu t-tilqim tal-ħosba meta kienu iżgħar jew li huma kbar wisq biex jirċevuha bħala tfal.</seg>
</tuv>
</tu>
<tu tuid="285">
<prop type="lengthRatio">0.9487179487179487</prop>
<tuv xml:lang="en">
<seg>Everyone should check if they have had the nationally recommended vaccinations, and consult a medical professional in case any catch-ups are needed.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kulħadd għandu jiċċekkja jekk kienx ħa t-tilqim rakkomandat b'mod nazzjonali, u jikkonsulta professjonist mediku f'każ li jkollu bżonn xi tilqim ta' rkupru.</seg>
</tuv>
</tu>
<tu tuid="286">
<prop type="lengthRatio">0.4166666666666667</prop>
<tuv xml:lang="en">
<seg>diphtheria</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xorta jistgħu jirkupraw.</seg>
</tuv>
</tu>
<tu tuid="287">
<prop type="lengthRatio">0.9393939393939394</prop>
<tuv xml:lang="en">
<seg>However, some vaccines provide immunity that decreases over time, known as ‘waning immunity'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, xi vaċċini jipprovdu immunità li tonqos maż-żmien, magħrufa bħala "immunità li tbatti".</seg>
</tuv>
</tu>
<tu tuid="288">
<prop type="lengthRatio">0.922077922077922</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination programmes for specific diseases may be organised.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jistgħu jiġu organizzati programmi ta' tilqim ta' rkupru għal mard speċifiku.</seg>
</tuv>
</tu>
<tu tuid="289">
<prop type="lengthRatio">1.1866666666666668</prop>
<tuv xml:lang="en">
<seg>Some people may have missed a vaccination or did not get the recommended number of doses.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi persuni setgħu tilfu tilqima jew ma ħadux in-numru rakkomandat ta' dożi.</seg>
</tuv>
</tu>
<tu tuid="290">
<prop type="lengthRatio">1.0077519379844961</prop>
<tuv xml:lang="en">
<seg>Read more: https://ec.europa.eu/health/vaccination/overview_en and https://ec.europa.eu/info/departments/health-and-food-safety_en</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aqra aktar: https://ec.europa.eu/health/vaccination/overview_mt u https://ec.europa.eu/info/departments/health-and-food-safety_mt</seg>
</tuv>
</tu>
<tu tuid="291">
<prop type="lengthRatio">0.9649122807017544</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ema.europa.eu /</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni żur: https://www.ema.europa.eu /</seg>
</tuv>
</tu>
<tu tuid="292">
<prop type="lengthRatio">0.9649122807017544</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ecdc.europa.eu/</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni żur: https://www.ecdc.europa.eu/</seg>
</tuv>
</tu>
<tu tuid="293">
<prop type="lengthRatio">0.8739495798319328</prop>
<tuv xml:lang="en">
<seg>Communication and scientific experts in these organisations are involved in developing the contents (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-esperti ta' komunikazzjoni u dawk xjentifiċi f'dawn l-organizzazzjonijiet huma involuti fl-iżvilupp tal-kontenut (1).</seg>
</tuv>
</tu>
<tu tuid="294">
<prop type="lengthRatio">0.8255451713395638</prop>
<tuv xml:lang="en">
<seg>The core functions cover a wide spectrum of activities: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-funzjonijiet ewlenin ikopru spettru wiesa' ta' attivitajiet: is-sorveljanza, l-informazzjoni dwar l-epidemiji, ir-rispons, il-parir xjentifiku, il-mikrobijoloġija, it-tħejjija, it-taħriġ dwar is-saħħa pubblika, ir-relazzjonijiet internazzjonali, il-komunikazzjoni dwar is-saħħa, u l-ġurnal xjentifiku Eurosurveillance.</seg>
</tuv>
</tu>
<tu tuid="295">
<prop type="lengthRatio">0.8743169398907104</prop>
<tuv xml:lang="en">
<seg>EMA and its scientific committees examine all available data and assess their benefits and risks before they are approved and while they are marketed in the EU.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA u l-kumitati xjentifiċi tagħha jeżaminaw id-data kollha disponibbli u jivvalutaw il-benefiċċji u r-riskji tagħhom qabel ma jiġu approvati u waqt li jiġu kkummerċjalizzati fl-UE.</seg>
</tuv>
</tu>
<tu tuid="296">
<prop type="lengthRatio">0.9356435643564357</prop>
<tuv xml:lang="en">
<seg>The European Medicines Agency (EMA) is a decentralized agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Aġenzija Ewropea għall-Mediċini (EMA) hija aġenzija deċentralizzata tal-Unjoni Ewropea (UE) responsabbli għall-evalwazzjoni xjentifika, is-superviżjoni u l-monitoraġġ tas-sikurezza tal-mediċini fl-UE.</seg>
</tuv>
</tu>
<tu tuid="297">
<prop type="lengthRatio">0.967741935483871</prop>
<tuv xml:lang="en">
<seg>To improve vaccination uptake, the Council adopted a Recommendation to strengthen the EU cooperation on vaccine-preventable diseases in December 2018.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Biex itejjeb it-teħid tat-tilqim, f'Diċembru 2018 il-Kunsill adotta Rakkomandazzjoni dwar kooperazzjoni msaħħa tal-UE kontra l-mard li jista' jiġi evitat .</seg>
</tuv>
</tu>
<tu tuid="298">
<prop type="lengthRatio">0.9396984924623115</prop>
<tuv xml:lang="en">
<seg>It is an initiative of the European Union and was developed following the Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases adopted in December 2018.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan huwa inizjattiva tal-Unjoni Ewropea u ġie żviluppat wara r- Rakkomandazzjoni tal-Kunsill dwar kooperazzjoni msaħħa kontra l-mard li jista' jiġi evitat bit-tilqim li ġiet adottata f'Diċembru 2018.</seg>
</tuv>
</tu>
<tu tuid="299">
<prop type="lengthRatio">0.9764705882352941</prop>
<tuv xml:lang="en">
<seg>The Commission is divided into departments that develop policies in specific areas.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni hija maqsuma f'dipartimenti li jiżviluppaw politiki f'oqsma speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="300">
<prop type="lengthRatio">0.8294314381270903</prop>
<tuv xml:lang="en">
<seg>In the area of vaccine-preventable diseases, ECDC provides regular surveillance data, e.g. the number of confirmed cases, and scientific advice on vaccines, monitors disease outbreaks and develops materials to support communication on immunisation.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fil-qasam tal-mard li jista' jiġi evitat bil-vaċċini, l-ECDC jipprovdi data regolari dwar is-sorveljanza, eż. l-għadd ta' każijiet ikkonfermati, u parir xjentifiku dwar il-vaċċini, jimmonitorja t-tifqigħat tal-mard u jiżviluppa materjali biex tiġi appoġġjata l-komunikazzjoni dwar l-immunizzazzjoni.</seg>
</tuv>
</tu>
<tu tuid="301">
<prop type="lengthRatio">0.9252336448598131</prop>
<tuv xml:lang="en">
<seg>(1) The European Commission, ECDC and EMA have mechanisms in place in order to ensure impartiality.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(1) Il-Kummissjoni Ewropea, l-ECDC u l-EMA għandhom mekkaniżmi fis-seħħ sabiex tiġi żgurata l-imparzjalità.</seg>
</tuv>
</tu>
<tu tuid="302">
<prop type="lengthRatio">0.7884615384615384</prop>
<tuv xml:lang="en">
<seg>One of the departments is DG for Health and Food Safety , responsible for EU policy on food safety and health and for monitoring the implementation of related laws.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Wieħed mid-dipartimenti huwa d- DĠ għas-Saħħa u s-Sikurezza Alimentari , responsabbli għall-politika tal-UE dwar is-saħħa u s-sikurezza alimentari u biex jimmonitorja l-implimentazzjoni ta' liġijiet relatati.</seg>
</tuv>
</tu>
<tu tuid="303">
<prop type="lengthRatio">0.7653061224489796</prop>
<tuv xml:lang="en">
<seg>Representatives from EU and EEA countries' public health organisations were consulted for finalising the website's contents and its language versions.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Rappreżentanti mill-organizzazzjonijiet tas-saħħa pubblika tal-pajjiżi tal-UE u taż-ŻEE ġew ikkonsultati biex jiġi ffinalizzat il-kontenut tas-sit web kif ukoll il-verżjonijiet lingwistiċi tiegħu.</seg>
</tuv>
</tu>
<tu tuid="304">
<prop type="lengthRatio">0.9571428571428572</prop>
<tuv xml:lang="en">
<seg>ECDC also maintains the Vaccine Scheduler , an online, interactive platform showing the vaccination schedules of all EU Member States.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ECDC iżomm ukoll Skeda tal-Vaċċini , li hija pjattaforma online u interattiva li turi l-iskedi tat-tilqim tal-Istati Membri kollha tal-UE.</seg>
</tuv>
</tu>
<tu tuid="305">
<prop type="lengthRatio">0.8010471204188482</prop>
<tuv xml:lang="en">
<seg>Staff and experts are required to declare any personal interest or any interest in any business or organisation that could compromise their impartiality.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-persunal u l-esperti huma meħtieġa jiddikjaraw kwalunkwe interess personali jew kwalunkwe interess fi kwalunkwe negozju jew organizzazzjoni li jista' jikkomprometti l-imparzjalità tagħhom.</seg>
</tuv>
</tu>
<tu tuid="306">
<prop type="lengthRatio">0.9004329004329005</prop>
<tuv xml:lang="en">
<seg>This is to ensure that staff and experts do not, in the performance of their duties, deal with matters in which they may, directly or indirectly, have a personal interest that could impair their independence.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan bil-għan li jiġi żgurat li, meta jwettqu l-kompiti tagħhom, il-persunal u l-esperti ma jindirizzawx kwistjonijiet li jista' jkollhom interess personali fihom, b'mod dirett jew indirett, li jista' jxekkel l-indipendenza tagħhom.</seg>
</tuv>
</tu>
<tu tuid="307">
<prop type="lengthRatio">0.7590361445783133</prop>
<tuv xml:lang="en">
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-għan tal-inizjattiva huwa li tindirizza l-eżitazzjoni għall-vaċċini, ittejjeb il-koordinazzjoni dwar l-akkwist tal-vaċċini, tappoġġja r-riċerka u l-innovazzjoni, u ssaħħaħ il-kooperazzjoni tal-UE b'rabta mal-mard li jista' jiġi evitat bil-vaċċini.</seg>
</tuv>
</tu>
<tu tuid="308">
<prop type="lengthRatio">0.9348659003831418</prop>
<tuv xml:lang="en">
<seg>This website was developed by the European Centre for Disease Prevention and Control (ECDC), in partnership with the European Commission, specifically, its Department on Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan is-sit web ġie żviluppat miċ-Ċentru Ewropew għall-Prevenzjoni u l-Kontroll tal-Mard (ECDC), bi sħubija mal-Kummissjoni Ewropea, speċifikament, mad-Dipartiment għas-Saħħa u s-Sikurezza Alimentari (DĠ SANTE) tagħha u mal-Aġenzija Ewropea għall-Mediċini (EMA).</seg>
</tuv>
</tu>
<tu tuid="309">
<prop type="lengthRatio">0.890625</prop>
<tuv xml:lang="en">
<seg>EMA ensures the efficacy, quality and safety of vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA tiżgura l-effikaċja, il-kwalità u s-sikurezza tal-vaċċini.</seg>
</tuv>
</tu>
<tu tuid="310">
<prop type="lengthRatio">0.9135802469135802</prop>
<tuv xml:lang="en">
<seg>The European Commission is the EU's politically independent executive arm.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni Ewropea hija l-fergħa eżekuttiva politikament independenti tal-UE.</seg>
</tuv>
</tu>
<tu tuid="311">
<prop type="lengthRatio">0.9619047619047619</prop>
<tuv xml:lang="en">
<seg>ECDC is an EU scientific agency aimed at strengthening Europe's defences against infectious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ECDC huwa aġenzija xjentifika tal-UE bil-għan li jissaħħu d-difiżi tal-Ewropa kontra mard li jittieħed.</seg>
</tuv>
</tu>
<tu tuid="312">
<prop type="lengthRatio">0.9609375</prop>
<tuv xml:lang="en">
<seg>EMA works closely with European and international partners and shares information on vaccines and good regulatory practice.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA taħdem mill-qrib mas-sħab Ewropej u internazzjonali u taqsam informazzjoni dwar il-vaċċini u l-prattika regolatorja tajba.</seg>
</tuv>
</tu>
<tu tuid="313">
<prop type="lengthRatio">2.272727272727273</prop>
<tuv xml:lang="en">
<seg>European Centre for Disease Prevention and Control</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="314">
<prop type="lengthRatio">0.8305084745762712</prop>
<tuv xml:lang="en">
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA hija organizzazzjoni ta' netwerking li l-attivitajiet tagħha jinvolvu lil eluf ta' esperti minn madwar l-Ewropa.</seg>
</tuv>
</tu>
<tu tuid="315">
<prop type="lengthRatio">1.0443037974683544</prop>
<tuv xml:lang="en">
<seg>It is alone responsible for drawing up proposals for new European legislation, and it implements the decisions of the European Parliament and the Council of the EU .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Waħedha hija responsabbli biex tfassal proposti għal leġiżlazzjoni Ewropea ġdida, u timplimenta d-deċiżjonijiet tal- Parlament Ewropew u tal- Kunsill tal-UE .</seg>
</tuv>
</tu>
<tu tuid="316">
<prop type="lengthRatio">0.9130434782608695</prop>
<tuv xml:lang="en">
<seg>non-productive cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>sogħla mhux produttiva.</seg>
</tuv>
</tu>
<tu tuid="317">
<prop type="lengthRatio">1.5</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Influwenza</seg>
</tuv>
</tu>
<tu tuid="318">
<prop type="lengthRatio">0.9466666666666667</prop>
<tuv xml:lang="en">
<seg>The 2009 A(H1N1)pdm09 influenza pandemic accounted for 123 000 to 203 000 deaths worldwide and a significant global socio-economic burden (3).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pandemija tal-influwenza 2009 A(H1N1)pdm09 ammontat għal bejn 123 000 u 203 000 mewta madwar id-dinja u piż soċjoekonomiku globali sinifikanti (3).</seg>
</tuv>
</tu>
<tu tuid="319">
<prop type="lengthRatio">0.9734513274336283</prop>
<tuv xml:lang="en">
<seg>The mortality rate due to influenza has been estimated in the EU/EEA countries participating to the EuroMOMO network (1) to be as high as 25 deaths per 100 000 population in the 2016/27 and 2017/18 influenza seasons (2).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rata ta' mortalità minħabba l-influwenza ġiet stmata fil-pajjiżi tal-UE/taż-ŻEE li pparteċipaw fin-netwerk EuroMOMO (1) bħala li laħqet sa 25 mewta għal kull 100 000 persuna fl-istaġuni tal-influwenza 2016/17 u 2017/18 (2).</seg>
</tuv>
</tu>
<tu tuid="320">
<prop type="lengthRatio">0.6363636363636364</prop>
<tuv xml:lang="en">
<seg>Who is at risk of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="321">
<prop type="lengthRatio">0.9626865671641791</prop>
<tuv xml:lang="en">
<seg>Approximately 20% of the population gets infected with influenza each year and one in four infected people will develop symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madwar 20 % tal-popolazzjoni tiġi infettata bl-influwenza kull sena u waħda minn kull erba' persuni infettati se tiżviluppa s-sintomi.</seg>
</tuv>
</tu>
<tu tuid="322">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>Complications of influenza include pneumonia and encephalitis (inflammation of the brain).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumplikazzjonijiet tal-influwenza jinkludu pnewmonja u enċefalite (infjammazzjoni tal-moħħ).</seg>
</tuv>
</tu>
<tu tuid="323">
<prop type="lengthRatio">0.9864864864864865</prop>
<tuv xml:lang="en">
<seg>A pandemic is the rapid spread of a new human influenza around the world.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pandemija hija t-tixrid rapidu ta' influwenza umana ġdida madwar id-dinja.</seg>
</tuv>
</tu>
<tu tuid="324">
<prop type="lengthRatio">0.9625</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs in regular annual epidemics in the winter season.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-Ewropa, l-influwenza sseħħ f'epidemiji annwali regolari fl-istaġun tax-xitwa.</seg>
</tuv>
</tu>
<tu tuid="325">
<prop type="lengthRatio">0.8401360544217688</prop>
<tuv xml:lang="en">
<seg>The EU Member States recommend seasonal influenza vaccination for risk groups, such as the elderly, as well as individuals with chronic medical conditions like heart disease, problems with the lungs and airways, diabetes or immune system problems.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Istati Membri tal-UE jirrakkomandaw tilqim kontra l-influwenza staġunali għall-gruppi li jinsabu f'riskju, bħall-anzjani, kif ukoll l-individwi b'kundizzjonijiet mediċi kroniċi bħal mard tal-qalb, problemi bil-pulmun u bil-pajpijiet tan-nifs, id-dijabete jew problemi bis-sistema immunitarja.</seg>
</tuv>
</tu>
<tu tuid="326">
<prop type="lengthRatio">0.9906103286384976</prop>
<tuv xml:lang="en">
<seg>In addition to vaccination, antiviral medicines have been shown to be safe and effective measures to prevent influenza infection or to reduce the severity of infection in certain settings, such as nursing homes.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra t-tilqim, il-mediċini antivirali ntwerew li huma miżuri siguri u effettivi biex tiġi evitata l-infezzjoni tal-influwenza jew biex titnaqqas is-severità tal-infezzjoni f'ċerti ambjenti, bħad-djar tal-kura.</seg>
</tuv>
</tu>
<tu tuid="327">
<prop type="lengthRatio">0.8805970149253731</prop>
<tuv xml:lang="en">
<seg>Vaccination is the most effective way to prevent influenza.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim huwa l-aktar mod effettiv biex tiġi evitata l-influwenza.</seg>
</tuv>
</tu>
<tu tuid="328">
<prop type="lengthRatio">0.775</prop>
<tuv xml:lang="en">
<seg>How can influenza be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="329">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>sore throat;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ ta' ras;</seg>
</tuv>
</tu>
<tu tuid="330">
<prop type="lengthRatio">1.0294117647058822</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tal-influwenza?</seg>
</tuv>
</tu>
<tu tuid="331">
<prop type="lengthRatio">0.4888888888888889</prop>
<tuv xml:lang="en">
<seg>(3) Simonsen L. et al.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal dawk li iva, is-sintomi komuni jinkludu:</seg>
</tuv>
</tu>
<tu tuid="332">
<prop type="lengthRatio">0.9</prop>
<tuv xml:lang="en">
<seg>What is influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="333">
<prop type="lengthRatio">0.8831168831168831</prop>
<tuv xml:lang="en">
<seg>Not everyone who is infected with an influenza virus becomes unwell.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Mhux kulħadd li jkun infettat b'virus tal-influwenza jibda jħossu ma jiflaħx.</seg>
</tuv>
</tu>
<tu tuid="334">
<prop type="lengthRatio">0.9279279279279279</prop>
<tuv xml:lang="en">
<seg>In addition to seasonal epidemics, novel influenza viruses may occasionally emerge and cause pandemics.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra l-epidemiji staġunali, xi drabi jistgħu jitfaċċaw viruses ta' influwenza ġodda li jikkawżaw pandemiji.</seg>
</tuv>
</tu>
<tu tuid="335">
<prop type="lengthRatio">0.7052238805970149</prop>
<tuv xml:lang="en">
<seg>For most cases of influenza, patients are advised to take bed rest and drink plenty of fluids in order to manage their symptoms; staying at home also minimises the risk of infecting others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-biċċa l-kbira tal-każijiet ta' influwenza, il-pazjenti jingħataw il-parir biex joqogħdu fis-sodda u jistrieħu filwaqt li jixorbu ħafna fluwidi sabiex jikkontrollaw is-sintomi tagħhom; il-fatt li persuna toqgħod id-dar inaqqas ir-riskju li tinfetta lil ħaddieħor.</seg>
</tuv>
</tu>
<tu tuid="336">
<prop type="lengthRatio">0.9396551724137931</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Organizzazzjoni Dinjija tas-Saħħa (WHO) tirrakkomanda wkoll it-tilqim għall-ħaddiema fil-qasam tal-kura tas-saħħa.</seg>
</tuv>
</tu>
<tu tuid="337">
<prop type="lengthRatio">0.7581395348837209</prop>
<tuv xml:lang="en">
<seg>Most EU Member States follow the WHO recommendations to vaccinate pregnant women, and some follow recommendations to vaccinate healthy children aged 6 - 59 months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-biċċa l-kbira tal-Istati Membri tal-UE jsegwu r-rakkomandazzjonijiet tad-WHO għat-tilqim tan-nisa tqal, u xi wħud isegwu r-rakkomandazzjonijiet għat-tilqim ta' tfal b'saħħithom li għandhom bejn 6 xhur u 59 xahar.</seg>
</tuv>
</tu>
<tu tuid="338">
<prop type="lengthRatio">1.0384615384615385</prop>
<tuv xml:lang="en">
<seg>Children are infected slightly more often than adults.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tfal jiġu infettati ftit aktar spiss mill-adulti.</seg>
</tuv>
</tu>
<tu tuid="339">
<prop type="lengthRatio">0.8698630136986302</prop>
<tuv xml:lang="en">
<seg>(1) EuroMOMO - European monitoring of excess mortality for public health action: http://www.euromomo.eu/methods/objectives.html</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-mediċini antivirali, meħuda malajr kemm jista' jkun wara li l-pazjent taqbdu l-marda, huma miżuri siguri u effettivi għall-kura tal-influwenza.</seg>
</tuv>
</tu>
<tu tuid="340">
<prop type="lengthRatio">1.0082644628099173</prop>
<tuv xml:lang="en">
<seg>Severe illness and complications are more common in very young infants, the frail elderly and certain medical risk groups.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Mard u kumplikazzjonijiet severi huma aktar komuni fi tfal żgħar ħafna, l-anzjani debboli u ċerti gruppi b'riskju mediku.</seg>
</tuv>
</tu>
<tu tuid="341">
<prop type="lengthRatio">0.5555555555555556</prop>
<tuv xml:lang="en">
<seg>How is influenza treated?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma l-kumplikazzjonijiet tal-influwenza?</seg>
</tuv>
</tu>
<tu tuid="342">
<prop type="lengthRatio">1.3083333333333333</prop>
<tuv xml:lang="en">
<seg>(2) Nielsen J. et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'xi każijiet, il-bnedmin jistgħu jiġu infettati mill-annimali, bħal fil-każijiet tal-influwenza tat-tjur u tal-ħnieżer.</seg>
</tuv>
</tu>
<tu tuid="343">
<prop type="lengthRatio">2.1052631578947367</prop>
<tuv xml:lang="en">
<seg>What are the complications of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ fil-griżmejn;</seg>
</tuv>
</tu>
<tu tuid="344">
<prop type="lengthRatio">0.7481481481481481</prop>
<tuv xml:lang="en">
<seg>An update of seasonal influenza vaccines is needed yearly, since influenza viruses constantly evolve.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull sena huwa meħtieġ aġġornament tat-tilqim kontra l-influwenza staġunali, peress li l-viruses tal-influwenza jevolvi b'mod kontinwu.</seg>
</tuv>
</tu>
<tu tuid="345">
<prop type="lengthRatio">0.8620689655172413</prop>
<tuv xml:lang="en">
<seg>In some cases patients develop bacterial complications following influenza infection and need to be treated with antibiotics.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'xi każijiet, il-pazjenti jiżviluppaw kumplikazzjonijiet batterjali wara infezzjoni tal-influwenza u jkollhom bżonn jiġu kkurati b'antibijotiċi.</seg>
</tuv>
</tu>
<tu tuid="346">
<prop type="lengthRatio">0.8255813953488372</prop>
<tuv xml:lang="en">
<seg>This is mainly via direct contact with secretions from infectious patients, such as droplets of fluid released when they cough or breathe out.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan iseħħ prinċipalment minħabba kuntatt dirett ma' sekrezzjonijiet minn pazjenti infettati, bħall-qtar żgħir ta' fluwidu li joħroġ meta jisogħlu jew jieħdu nifs 'il barra.</seg>
</tuv>
</tu>
<tu tuid="347">
<prop type="lengthRatio">0.7857142857142857</prop>
<tuv xml:lang="en">
<seg>Animals can also be infected with influenza.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-annimali jistgħu jiġu infettati wkoll mill-influwenza.</seg>
</tuv>
</tu>
<tu tuid="348">
<prop type="lengthRatio">0.8282828282828283</prop>
<tuv xml:lang="en">
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'każijiet mhux ikkumplikati, is-sintomi jgħaddu b'mod spontanju fi żmien ġimgħa minn meta taqbdek.</seg>
</tuv>
</tu>
<tu tuid="349">
<prop type="lengthRatio">1.962962962962963</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa rrakkomandat li l-pazjenti jfittxu parir mediku jekk il-kundizzjoni tagħhom tkompli taqleb għall-agħar.</seg>
</tuv>
</tu>
<tu tuid="350">
<prop type="lengthRatio">1.0232558139534884</prop>
<tuv xml:lang="en">
<seg>It analyses many sources of data, including:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din tanalizza bosta sorsi ta' data, inkluż:</seg>
</tuv>
</tu>
<tu tuid="351">
<prop type="lengthRatio">0.8666666666666667</prop>
<tuv xml:lang="en">
<seg>information shared by other regulators.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>informazzjoni kondiviża minn regolaturi oħra.</seg>
</tuv>
</tu>
<tu tuid="352">
<prop type="lengthRatio">0.8666666666666667</prop>
<tuv xml:lang="en">
<seg>For more information, see:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara:</seg>
</tuv>
</tu>
<tu tuid="353">
<prop type="lengthRatio">0.8695652173913043</prop>
<tuv xml:lang="en">
<seg>reports from patients, parents and healthcare professionals;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>rapporti minn pazjenti, ġenituri u professjonisti tal-kura tas-saħħa;</seg>
</tuv>
</tu>
<tu tuid="354">
<prop type="lengthRatio">0.8682926829268293</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ladarba vaċċin jiġi approvat għall-użu, l-awtoritajiet nazzjonali tal-UE/taż-ŻEE u l- Aġenzija Ewropea għall-Mediċini (EMA), jimmonitorjaw kontinwament l-effetti sekondarji fuq in-nies li rċevew il-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="355">
<prop type="lengthRatio">0.7142857142857143</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety & reporting side effects</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Monitoraġġ tas-sikurezza tal-vaċċin u rappurtar ta' effetti sekondarji</seg>
</tuv>
</tu>
<tu tuid="356">
<prop type="lengthRatio">0.75</prop>
<tuv xml:lang="en">
<seg>Information on these reported suspected side effects is publicly available on the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar dawn l-effetti sekondarji suspettati rrapportati hija disponibbli għall-pubbliku fuq il- bażi tad-data Ewropea ta' rapporti dwar reazzjoni avversa għal mediċina suspettata .</seg>
</tuv>
</tu>
<tu tuid="357">
<prop type="lengthRatio">0.944954128440367</prop>
<tuv xml:lang="en">
<seg>The process of monitoring the safety and managing the risks of medicines is called ‘pharmacovigilance'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-proċess tal-monitoraġġ tas-sikurezza u l-immaniġġjar tar-riskji tal-mediċini jissejjaħ "farmakoviġilanza".</seg>
</tuv>
</tu>
<tu tuid="358">
<prop type="lengthRatio">0.8042553191489362</prop>
<tuv xml:lang="en">
<seg>More information on how to report suspected side effects can be found in the prescribing information or package leaflet or the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar informazzjoni dwar kif tirrapporta effetti sekondarji suspettati tinstab fl-informazzjoni tal-preskrizzjoni jew fil-fuljett ta' tagħrif jew fil- bażi tad-data Ewropea ta' rapporti dwar reazzjoni avversa għal mediċina suspettata .</seg>
</tuv>
</tu>
<tu tuid="359">
<prop type="lengthRatio">0.7475728155339806</prop>
<tuv xml:lang="en">
<seg>Patients, healthcare professionals and pharmaceutical companies should report all suspected side effects to their national medicines regulatory authority.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pazjenti, il-professjonisti fil-qasam tal-kura tas-saħħa u l-kumpaniji farmaċewtiċi għandhom jirrapportaw l-effetti sekondarji suspettati kollha lill-awtorità regolatorja tal-mediċini nazzjonali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="360">
<prop type="lengthRatio">0.9316239316239316</prop>
<tuv xml:lang="en">
<seg>EMA carefully assesses suspected side effects to determine if there is a causal link with the vaccine or not.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA tanalizza bir-reqqa effetti sekondarji suspettati biex tiddetermina jekk hemmx rabta kawżali mal-vaċċin jew le.</seg>
</tuv>
</tu>
<tu tuid="361">
<prop type="lengthRatio">0.9</prop>
<tuv xml:lang="en">
<seg>When needed, EMA and the other European regulators take action.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta jkun meħtieġ, l-EMA u r-regolaturi Ewropej l-oħra jieħdu azzjoni.</seg>
</tuv>
</tu>
<tu tuid="362">
<prop type="lengthRatio">0.8105263157894737</prop>
<tuv xml:lang="en">
<seg>EMA checks new information on the safety of all vaccines available in Europe.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA tiċċekkja informazzjoni ġdida dwar is-sikurezza tal-vaċċini kollha disponibbli fl-Ewropa.</seg>
</tuv>
</tu>
<tu tuid="363">
<prop type="lengthRatio">1.3541666666666667</prop>
<tuv xml:lang="en">
<seg>This helps to rule out the possibility that it was a coincidence or that it was caused by factors unrelated to the vaccine itself.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jiżgura li kwalunkwe riskju possibbli jiġi identifikat u mmaniġġjat malajr kemm jista' jkun.</seg>
</tuv>
</tu>
<tu tuid="364">
<prop type="lengthRatio">0.8155339805825242</prop>
<tuv xml:lang="en">
<seg>(4) US CDC Pink Book - Measles: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(4) Pink Book tas-CDC tal-Istati Uniti - Il-Ħosba: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg>
</tuv>
</tu>
<tu tuid="365">
<prop type="lengthRatio">0.9371980676328503</prop>
<tuv xml:lang="en">
<seg>measles is highly contagious and 3 out of 10 people affected develop complications (4), which can include ear infection, diarrhoea, pneumonia and encephalitis (inflammation of the brain tissue);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-ħosba tittieħed ħafna u 3 minn kull 10 persuni milquta jiżviluppaw kumplikazzjonijiet (4), li jistgħu jinkludu infezzjoni tal-widnejn, dijarea, pulmonite u enċefalite (infjammazzjoni tat-tessut tal-moħħ);</seg>
</tuv>
</tu>
<tu tuid="366">
<prop type="lengthRatio">0.9950248756218906</prop>
<tuv xml:lang="en">
<seg>This list with examples includes diseases for which vaccines are included in the national immunisation programmes, and/or are given to persons considered to be at a higher risk of getting the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din il-lista b'eżempji tinkludi mard li t-tilqim tiegħu huwa inkluż fil-programmi nazzjonali tal-immunizzazzjoni, u/jew jingħata lil persuni li jitqiesu li jinsabu f'riskju ogħla li taqbadhom il-marda.</seg>
</tuv>
</tu>
<tu tuid="367">
<prop type="lengthRatio">0.8652173913043478</prop>
<tuv xml:lang="en">
<seg>almost 9 out of 10 babies born to mothers who had rubella in early pregnancy, will suffer from congenital rubella syndrome (with conditions such as deafness, cataracts and learning disabilities) (2);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kważi 9 minn kull 10 trabi li jitwieldu minn ommijiet li kellhom ir-rubella fil-bidu tat-tqala, se jbatu minn sindrome ta' rubella konġenitali (b'kondizzjonijiet bħal nuqqas ta' smigħ, katarretti u diżabilitajiet fit-tagħlim) (2);</seg>
</tuv>
</tu>
<tu tuid="368">
<prop type="lengthRatio">1.073394495412844</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for their health, for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-individwi kontra mard li jista' jkollu konsegwenzi serji fuq saħħithom, pereżempju:</seg>
</tuv>
</tu>
<tu tuid="369">
<prop type="lengthRatio">0.8432835820895522</prop>
<tuv xml:lang="en">
<seg>(2) ECDC factsheet - Congenital Rubella Syndrome: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(2) Skeda informattiva tal-ECDC - Is-Sindrome ta' Rubella Konġenitali: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
</tu>
<tu tuid="370">
<prop type="lengthRatio">0.8142292490118577</prop>
<tuv xml:lang="en">
<seg>meningococcal disease kills 1 in 10 people affected, even with prompt diagnosis and treatment, while problems including neurological or hearing impairment and amputation occur in up to 20% of survivors (3);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-marda meningokokkali toqtol 1 minn kull 10 persuni milquta, anki b'dijanjożi u trattament mill-ewwel, filwaqt li problemi li jinkludu insuffiċjenza newroloġika jew fis-smigħ u qtugħ ta' parti tal-ġisem iseħħu f'sa 20 % ta' dawk li jibqgħu ħajjin (3);</seg>
</tuv>
</tu>
<tu tuid="371">
<prop type="lengthRatio">0.8494623655913979</prop>
<tuv xml:lang="en">
<seg>(1) ECDC factsheet - Diphtheria: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(1) Skeda informattiva tal-ECDC - Id-Difterja: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
</tu>
<tu tuid="372">
<prop type="lengthRatio">0.8279569892473119</prop>
<tuv xml:lang="en">
<seg>(5) ECDC factsheet - Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(5) Skeda informattiva tal-ECDC - Il-Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="373">
<prop type="lengthRatio">0.9622641509433962</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death (5).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumplikazzjonijiet jinkludu pulmonite, enċefalopatija (marda tal-moħħ), aċċessjonijiet u anki mewt (5).</seg>
</tuv>
</tu>
<tu tuid="374">
<prop type="lengthRatio">0.8974358974358975</prop>
<tuv xml:lang="en">
<seg>(3) ECDC factsheet - Meningococcal disease: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(3) Skeda informattiva tal-ECDC - Marda meningokokkali: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg>
</tuv>
</tu>
<tu tuid="375">
<prop type="lengthRatio">0.8705882352941177</prop>
<tuv xml:lang="en">
<seg>diphtheria kills 1 in every 10 people who get it, even with treatment (1);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>id-difterja toqtol 1 minn kull 10 persuni li taqbadhom, anki jekk tiġi ttrattata (1);</seg>
</tuv>
</tu>
<tu tuid="376">
<prop type="lengthRatio">0.7383720930232558</prop>
<tuv xml:lang="en">
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-pertussis (sogħla konvulżiva) tista' partikolarment tkun serja fit-tfal żgħar, u tikkawża episodji ta' ħin twil fejn wieħed jisgħol li jistgħu jerġgħu jseħħu sa xahrejn.</seg>
</tuv>
</tu>
<tu tuid="377">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>An example is aluminium;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Eżempju huwa l-aluminju;</seg>
</tuv>
</tu>
<tu tuid="378">
<prop type="lengthRatio">0.9408284023668639</prop>
<tuv xml:lang="en">
<seg>There may also be trace amounts of other substances used in the manufacturing process, such as ovalbumin (a protein found in eggs) or neomycin (an antibiotic).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jista' jkun hemm ukoll traċċi ta' sustanzi oħra użati fil-proċess ta' manifattura, bħall-albumina tal-bajd (proteina li tinsab fil-bajd) jew in-neomiċina (antibijotiku).</seg>
</tuv>
</tu>
<tu tuid="379">
<prop type="lengthRatio">0.8053097345132744</prop>
<tuv xml:lang="en">
<seg>Regulators check that their benefits are weighed against the risk of any reactions to them.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-regolaturi jivverifikaw li l-benefiċċji tagħhom jiġu ppeżati kontra r-riskju ta' kwalunkwe reazzjoni għalihom.</seg>
</tuv>
</tu>
<tu tuid="380">
<prop type="lengthRatio">0.9345794392523364</prop>
<tuv xml:lang="en">
<seg>excipients: these are inactive ingredients, like water, or sodium chloride (salt), as well as the preservatives or stabilisers that help the vaccine remain unchanged during storage, keeping it active.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>eċċipjenti: dawn huma ingredjenti inattivi, bħall-ilma, jew il-klorur tas-sodju (melħ), kif ukoll il-preservattivi jew l-istabbilizzaturi li jgħinu lill-vaċċin jibqa' l-istess matul il-ħżin, u b'hekk jinżamm attiv.</seg>
</tuv>
</tu>
<tu tuid="381">
<prop type="lengthRatio">0.8819444444444444</prop>
<tuv xml:lang="en">
<seg>adjuvants: these improve the immune response to the vaccine by making the response stronger, faster and more sustained in time.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>aġġuvanti: dawn itejbu r-reazzjoni immuni għall-vaċċin billi eventwalment jagħmlu r-reazzjoni aktar b'saħħitha, aktar rapida u aktar prolungata.</seg>
</tuv>
</tu>
<tu tuid="382">
<prop type="lengthRatio">1.1666666666666667</prop>
<tuv xml:lang="en">
<seg>In addition to one or more antigens, there are other components in a vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra antiġene wieħed jew aktar, f'vaċċin hemm komponenti oħra.</seg>
</tuv>
</tu>
<tu tuid="383">
<prop type="lengthRatio">1.7073170731707317</prop>
<tuv xml:lang="en">
<seg>For example, the package leaflet will state if there are special precautions for use of a vaccine in people with certain allergies, such as vaccines including trace amounts of egg in people with an egg allergy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn is-sustanzi jiġu kkontrollati b'mod konsistenti biex jiġi żgurat li jkunu preżenti f'livelli li ntwera li huma sikuri.</seg>
</tuv>
</tu>
<tu tuid="384">
<prop type="lengthRatio">0.8622448979591837</prop>
<tuv xml:lang="en">
<seg>For more information about national vaccination programmes, see the ECDC vaccine scheduler and visit the official websites on immunisation of the EU/EEA countries here .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni dwar il-programmi nazzjonali tat-tilqim, ara l- iskedatur tal-vaċċini tal-ECDC u żur is-siti web uffiċjali dwar l-immunizzazzjoni tal-pajjiżi tal-UE/taż-ŻEE minnhawnhekk .</seg>
</tuv>
</tu>
<tu tuid="385">
<prop type="lengthRatio">0.9468085106382979</prop>
<tuv xml:lang="en">
<seg>Some vaccines protect against only one disease, but others protect against more than one.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi vaċċini jipproteġu kontra marda waħda biss, iżda oħrajn jipproteġu kontra aktar minn waħda.</seg>
</tuv>
</tu>
<tu tuid="386">
<prop type="lengthRatio">0.8859649122807017</prop>
<tuv xml:lang="en">
<seg>Sometimes, more than one vaccine may be given at once to protect against several infectious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi drabi, jista' jingħata aktar minn vaċċin wieħed fl-istess ħin biex jipproteġi kontra diversi mardiet infettivi.</seg>
</tuv>
</tu>
<tu tuid="387">
<prop type="lengthRatio">0.8262548262548263</prop>
<tuv xml:lang="en">
<seg>In addition, vaccines to protect against specific diseases are sometimes recommended for ‘high-risk' groups, such as people with long-term health conditions or people planning to travel to other parts of the world.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Barra minn hekk, il-vaċċini li jipproteġu kontra mard speċifiku xi drabi huma rakkomandati għal gruppi ta' "riskju għoli", bħal persuni b'kundizzjonijiet tas-saħħa għal perjodu twil ta' żmien jew persuni li beħsiebhom jivvjaġġaw lejn partijiet oħra tad-dinja.</seg>
</tuv>
</tu>
<tu tuid="388">
<prop type="lengthRatio">0.9647887323943662</prop>
<tuv xml:lang="en">
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-biċċa l-kbira tal-programmi nazzjonali tat-tiqim fl-UE/fiż-ŻEE jinkludu vaċċini sa għoxrin marda li jingħataw lin-nies f'etajiet speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="389">
<prop type="lengthRatio">0.896551724137931</prop>
<tuv xml:lang="en">
<seg>Combined use of vaccines is well established and based on scientific studies on its benefits and safety.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-użu kkombinat tal-vaċċini huwa stabbilit sew u bbażat fuq studji xjentifiċi dwar il-benefiċċji u s-sigurtà tiegħu.</seg>
</tuv>
</tu>
<tu tuid="390">
<prop type="lengthRatio">0.9245283018867925</prop>
<tuv xml:lang="en">
<seg>This is based on local conditions, such as how common the disease is, as well as economic factors.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan huwa bbażat fuq il-kundizzjonijiet lokali, bħal kemm hija komuni l-marda, kif ukoll fatturi ekonomiċi.</seg>
</tuv>
</tu>
<tu tuid="391">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>Decisions on vaccines in use in different European countries</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Deċiżjonijiet dwar il-vaċċini li jintużaw f'pajjiżi Ewropej differenti</seg>
</tuv>
</tu>
<tu tuid="392">
<prop type="lengthRatio">0.890625</prop>
<tuv xml:lang="en">
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni u links għas-siti web tal-membri tal-VSN huma disponibbli hawnhekk: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
</tu>
<tu tuid="393">
<prop type="lengthRatio">0.9736842105263158</prop>
<tuv xml:lang="en">
<seg>It usually occurs within minutes of exposure to the source of the allergy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Normalment din isseħħ ftit minuti wara l-esponiment għas-sors tal-allerġija.</seg>
</tuv>
</tu>
<tu tuid="394">
<prop type="lengthRatio">1.4666666666666666</prop>
<tuv xml:lang="en">
<seg>For up-to-date information on COVID-19, see:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara:</seg>
</tuv>
</tu>
<tu tuid="395">
<prop type="lengthRatio">0.8846153846153846</prop>
<tuv xml:lang="en">
<seg>The Vaccine Safety Net (VSN) is a global network of websites, established by the World Health Organization, that provides reliable information on vaccine safety.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Vaccine Safety Net (VSN) hija netwerk globali ta' siti web, stabbiliti mill-Organizzazzjoni Dinjija tas-Saħħa, li tipprovdi informazzjoni affidabbli dwar is-sikurezza tal-vaċċini.</seg>
</tuv>
</tu>
<tu tuid="396">
<prop type="lengthRatio">0.9064516129032258</prop>
<tuv xml:lang="en">
<seg>Certain immune system disorders (e.g. congenital immune deficiencies), or medical treatments (e.g. chemotherapy, a bone marrow or other organ transplant, or high doses of steroids) are contraindications for some vaccines, such as measles, mumps, rubella, varicella or oral typhoid.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ċerti disturbi tas-sistema immunitarja (eż. disturbi immuni konġenitali), jew kuri mediċi (eż. kimoterapija, trapjant tal-mudullun jew ta' kwalunkwe organu ieħor, jew dożi għoljin ta' sterojdi) huma kontraindikazzjonijiet għal ċerti vaċċini, bħall-ħosba, il-gattone, ir-rubella, il-variċella jew tifojde orali.</seg>
</tuv>
</tu>
<tu tuid="397">
<prop type="lengthRatio">0.8363636363636363</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rubella (il-ħosba Ġermaniża) hija infezzjoni virali.</seg>
</tuv>
</tu>
<tu tuid="398">
<prop type="lengthRatio">1.2083333333333333</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif jiġi ttrattat l-HPV?</seg>
</tuv>
</tu>
<tu tuid="399">
<prop type="lengthRatio">0.8564102564102564</prop>
<tuv xml:lang="en">
<seg>Immunocompromised patients also benefit from those around them being fully vaccinated (such as family members, caregivers), as then they are also indirectly protected.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pazjenti immunokompromessi jibbenefikaw ukoll mill-fatt li dawk ta' madwarhom ikunu tlaqqmu b'mod komplet (bħall-membri tal-familja, l-indokraturi), peress li b'mod indirett ikunu protetti wkoll.</seg>
</tuv>
</tu>
<tu tuid="400">
<prop type="lengthRatio">1.1791044776119404</prop>
<tuv xml:lang="en">
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim huwa l-aktar mod effettiv biex tiġi evitata l-influwenza.</seg>
</tuv>
</tu>
<tu tuid="401">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni dwar in-netwerk żur: https://vaccinesafetynet.org .</seg>
</tuv>
</tu>
<tu tuid="402">
<prop type="lengthRatio">0.8260869565217391</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-infezzjoni tal-virus tal-papilloma uman (HPV) hija infezzjoni virali li tiġi trażmessa l-aktar sesswalment permezz ta' kuntatt dirett...</seg>
</tuv>
</tu>
<tu tuid="403">
<prop type="lengthRatio">1.6583333333333334</prop>
<tuv xml:lang="en">
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it. Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kontraindikazzjonijiet possibbli għandhom dejjem jiġu diskussi mal-fornitur tal-kura tas-saħħa qabel ma jingħata vaċċin.</seg>
</tuv>
</tu>
<tu tuid="404">
<prop type="lengthRatio">0.7580645161290323</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar skedi informattivi se jiġu inklużi fi stadju aktar tard.</seg>
</tuv>
</tu>
<tu tuid="405">
<prop type="lengthRatio">0.8958333333333334</prop>
<tuv xml:lang="en">
<seg>Official websites from EU and EEA countries</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Siti web uffiċjali mill-pajjiżi tal-UE u taż-ŻEE</seg>
</tuv>
</tu>
<tu tuid="406">
<prop type="lengthRatio">1.0256410256410255</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="407">
<prop type="lengthRatio">1.1627906976744187</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="408">
<prop type="lengthRatio">1.6936936936936937</prop>
<tuv xml:lang="en">
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra l-epidemiji staġunali, xi drabi jistgħu jitfaċċaw viruses ta' influwenza ġodda li jikkawżaw pandemiji.</seg>
</tuv>
</tu>
<tu tuid="409">
<prop type="lengthRatio">1.5961538461538463</prop>
<tuv xml:lang="en">
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tfal jiġu infettati ftit aktar spiss mill-adulti.</seg>
</tuv>
</tu>
<tu tuid="410">
<prop type="lengthRatio">0.8787878787878788</prop>
<tuv xml:lang="en">
<seg>How can measles be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta għandu jiġi evitat it-tilqim</seg>
</tuv>
</tu>
<tu tuid="411">
<prop type="lengthRatio">0.7352941176470589</prop>
<tuv xml:lang="en">
<seg>How can HPV be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-HPV, kif tista' tiġi pprevenuta?</seg>
</tuv>
</tu>
<tu tuid="412">
<prop type="lengthRatio">2.4375</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for individuals</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Reazzjoni immuni</seg>
</tuv>
</tu>
<tu tuid="413">
<prop type="lengthRatio">1.5963302752293578</prop>
<tuv xml:lang="en">
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-individwi kontra mard li jista' jkollu konsegwenzi serji fuq saħħithom, pereżempju:</seg>
</tuv>
</tu>
<tu tuid="414">
<prop type="lengthRatio">1.1666666666666667</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi kkurata l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="415">
<prop type="lengthRatio">1.0357142857142858</prop>
<tuv xml:lang="en">
<seg>Some vaccines are contraindicated during pregnancy, such as measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi vaċċini jkunu kontraindikati matul it-tqala, bħall-ħosba, il-gattone u r-rubella.</seg>
</tuv>
</tu>
<tu tuid="416">
<prop type="lengthRatio">1.608695652173913</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tista' tinfirex malajr.</seg>
</tuv>
</tu>
<tu tuid="417">
<prop type="lengthRatio">0.8473282442748091</prop>
<tuv xml:lang="en">
<seg>There may be other contraindications for specific vaccines, which need discussing with the healthcare provider.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jista' jkun hemm kontraindikazzjonijiet oħra għal vaċċini speċifiċi, li jkunu jeħtieġu diskussjoni mal-fornitur tal-kura tas-saħħa.</seg>
</tuv>
</tu>
<tu tuid="418">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>previous contact with the disease;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>iż-żmien minn mindu jkunu tlaqqmu;</seg>
</tuv>
</tu>
<tu tuid="419">
<prop type="lengthRatio">0.8968253968253969</prop>
<tuv xml:lang="en">
<seg>Anaphylaxis is a rare, rapid, extreme allergic reaction which can cause shock, swelling and difficulty breathing.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-anafilassi hija reazzjoni allerġika estrema, mgħaġġla u rari li tista' tikkawża xokk, nefħa u diffikultà fit-teħid tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="420">
<prop type="lengthRatio">0.9171974522292994</prop>
<tuv xml:lang="en">
<seg>A history of 'anaphylactic' or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Storja ta' reazzjoni "anafilattika" jew reazzjoni allerġika serja oħra wara li jkun ingħata vaċċin hija kontraindikazzjoni għal aktar dożi ta' dak il-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="421">
<prop type="lengthRatio">1.1311475409836065</prop>
<tuv xml:lang="en">
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-protezzjoni massima huma meħtieġa żewġ dożi tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="422">
<prop type="lengthRatio">2.1267605633802815</prop>
<tuv xml:lang="en">
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara l-iskeda informattiva dwar il-pertussis .</seg>
</tuv>
</tu>
<tu tuid="423">
<prop type="lengthRatio">0.8888888888888888</prop>
<tuv xml:lang="en">
<seg>What are the complications of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma l-kumplikazzjonijiet tal-influwenza?</seg>
</tuv>
</tu>
<tu tuid="424">
<prop type="lengthRatio">0.7986577181208053</prop>
<tuv xml:lang="en">
<seg>When looking at health-related information, it can be difficult to judge the quality and accuracy of information found.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta wieħed iħares lejn l-informazzjoni relatata mas-saħħa, jaf ikun diffiċli li wieħed jiġġudika l-kwalità u l-preċiżjoni tal-informazzjoni misjuba.</seg>
</tuv>
</tu>
<tu tuid="425">
<prop type="lengthRatio">0.8285714285714286</prop>
<tuv xml:lang="en">
<seg>How can rubella be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="426">
<prop type="lengthRatio">0.6595744680851063</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Portal Ewropew ta 'Informazzjoni dwar it-Tilqim</seg>
</tuv>
</tu>
<tu tuid="427">
<prop type="lengthRatio">0.8580645161290322</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age groups, often for infants and children, but also for teenagers, adults and elderly people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini huma rrakkomandati għal gruppi ta' etajiet differenti, ħafna drabi għat-trabi u t-tfal, iżda wkoll għall-adolexxenti, l-adulti u n-nies anzjani.</seg>
</tuv>
</tu>
<tu tuid="428">
<prop type="lengthRatio">0.9171597633136095</prop>
<tuv xml:lang="en">
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-awtoritajiet regolatorji tal-mediċini jistgħu jagħmlu spezzjonijiet biex jiżguraw li l-informazzjoni li jipprovdi l-iżviluppatur tal-vaċċin hija ta' min joqgħod fuqha.</seg>
</tuv>
</tu>
<tu tuid="429">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa rrakkomandat li l-pazjenti jfittxu parir mediku jekk il-kundizzjoni tagħhom tkompli taqleb għall-agħar.</seg>
</tuv>
</tu>
<tu tuid="430">
<prop type="lengthRatio">1.0434782608695652</prop>
<tuv xml:lang="en">
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, in-nies ma jistgħux jiddependu fuq l-immunità komunitarja għal xi mard infettiv.</seg>
</tuv>
</tu>
<tu tuid="431">
<prop type="lengthRatio">0.88</prop>
<tuv xml:lang="en">
<seg>(3) Simonsen L. et al.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi kkurata l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="432">
<prop type="lengthRatio">2.3220338983050848</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull min mhuwiex imlaqqam kontra l-ħosba jew li ma kellux il-marda jinsab f'riskju li taqbdu l-ħosba fi kwalunkwe età.</seg>
</tuv>
</tu>
<tu tuid="433">
<prop type="lengthRatio">2.176470588235294</prop>
<tuv xml:lang="en">
<seg>PLoS Med. 2013 Nov; 10(11): e1001558.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Antikorpi&nbsp;3.</seg>
</tuv>
</tu>
<tu tuid="434">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>Influenza is easily transmitted from person to person.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ħosba tinfirex faċilment fost individwi mhux imlaqqma.</seg>
</tuv>
</tu>
<tu tuid="435">
<prop type="lengthRatio">0.5066666666666667</prop>
<tuv xml:lang="en">
<seg>What are the complications of measles?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Liema huma l-effetti sekondarji l-aktar komuni fuq perjodu ta' żmien qasir?</seg>
</tuv>
</tu>
<tu tuid="436">
<prop type="lengthRatio">1.9156626506024097</prop>
<tuv xml:lang="en">
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn l-epidemiji huma assoċjati ma' rati għoljin ta' rikoveri l-isptar u mortalità.</seg>
</tuv>
</tu>
<tu tuid="437">
<prop type="lengthRatio">1.0104166666666667</prop>
<tuv xml:lang="en">
<seg>Pneumonia is a potential serious complication that has led to the death of some measles patients.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jiżgura li kwalunkwe riskju possibbli jiġi identifikat u mmaniġġjat malajr kemm jista' jkun.</seg>
</tuv>
</tu>
<tu tuid="438">
<prop type="lengthRatio">2.6166666666666667</prop>
<tuv xml:lang="en">
<seg>(2) Nielsen J. et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ewwel tilqima ġiet żviluppata fis-seklu 18 fir-Renju Unit.</seg>
</tuv>
</tu>
<tu tuid="439">
<prop type="lengthRatio">0.7692307692307693</prop>
<tuv xml:lang="en">
<seg>They can include mild fever, or pain or redness at the injection site.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din tiġi kkawżata minn batterji fil-ħalq, fl-imnieħer u fil-griżmejn ta' persuna infettata.</seg>
</tuv>
</tu>
<tu tuid="440">
<prop type="lengthRatio">1.5806451612903225</prop>
<tuv xml:lang="en">
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-influwenza hija trażmessa faċilment minn persuna għall-oħra.</seg>
</tuv>
</tu>
<tu tuid="441">
<prop type="lengthRatio">0.7330097087378641</prop>
<tuv xml:lang="en">
<seg>Healthcare professionals (e.g. doctors, nurses) have a role in ensuring that patients in their care receive the recommended vaccines at the right time.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pazjenti, il-professjonisti fil-qasam tal-kura tas-saħħa u l-kumpaniji farmaċewtiċi għandhom jirrapportaw l-effetti sekondarji suspettati kollha lill-awtorità regolatorja tal-mediċini nazzjonali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="442">
<prop type="lengthRatio">1.8073394495412844</prop>
<tuv xml:lang="en">
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis fi trabi mhux imlaqqma jew trabi li ommhom ma kinitx imlaqqma tista' tkun partikolarment severa.</seg>
</tuv>
</tu>
<tu tuid="443">
<prop type="lengthRatio">2.054054054054054</prop>
<tuv xml:lang="en">
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn sempliċiment jikkunsidraw ċirkostanzi u sistemi tas-saħħa differenti.</seg>
</tuv>
</tu>
<tu tuid="444">
<prop type="lengthRatio">2.0833333333333335</prop>
<tuv xml:lang="en">
<seg>The most severe forms of pertussis are in infants.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xorta jistgħu jirkupraw.</seg>
</tuv>
</tu>
<tu tuid="445">
<prop type="lengthRatio">0.8865979381443299</prop>
<tuv xml:lang="en">
<seg>Below are links to official websites with information on vaccination from public health organisations of the European Union (EU) and European Economic Area (EEA) countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hawn taħt hawn il-links għas-siti web uffiċjali b'informazzjoni dwar it-tilqim mill-organizzazzjonijiet tas-saħħa pubblika tal-pajjiżi tal-Unjoni Ewropea (UE) u taż-Żona Ekonomika Ewropea (ŻEE).</seg>
</tuv>
</tu>
<tu tuid="446">
<prop type="lengthRatio">1.1884057971014492</prop>
<tuv xml:lang="en">
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tikka fin-nofs tirrappreżenta persuna waħda affettwata minn marda.</seg>
</tuv>
</tu>
<tu tuid="447">
<prop type="lengthRatio">2.0217391304347827</prop>
<tuv xml:lang="en">
<seg>The severity of the disease varies widely, from no symptoms at all through to severe illness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Illum il-ġurnata, hemm tilqim għal ħafna mard.</seg>
</tuv>
</tu>
<tu tuid="448">
<prop type="lengthRatio">1.4415584415584415</prop>
<tuv xml:lang="en">
<seg>This may involve looking at vaccination records or the vaccination schedules in place when the person was born.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jistgħu jiġu organizzati programmi ta' tilqim ta' rkupru għal mard speċifiku.</seg>
</tuv>
</tu>
<tu tuid="449">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ġidri, illum il-ġurnatanqerdet mid-dinja kollha fil-bnedmin bis-saħħa tat-tilqim.</seg>
</tuv>
</tu>
<tu tuid="450">
<prop type="lengthRatio">0.8924731182795699</prop>
<tuv xml:lang="en">
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis hija marda batterika infettiva ħafna li tinvolvi l-pulmun u l-passaġġi tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="451">
<prop type="lengthRatio">1.0416666666666667</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sors: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
</tu>
<tu tuid="452">
<prop type="lengthRatio">0.8666666666666667</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV)</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Virus tal-papilloma uman (HPV)</seg>
</tuv>
</tu>
<tu tuid="453">
<prop type="lengthRatio">0.967741935483871</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(5) Skeda informattiva tal-ECDC - Il-Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="454">
<prop type="lengthRatio">1.1578947368421053</prop>
<tuv xml:lang="en">
<seg>fever or feverishness;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ fil-griżmejn;</seg>
</tuv>
</tu>
<tu tuid="455">
<prop type="lengthRatio">2.0833333333333335</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety & reporting side effects</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar skedi informattivi</seg>
</tuv>
</tu>
<tu tuid="456">
<prop type="lengthRatio">1.4666666666666666</prop>
<tuv xml:lang="en">
<seg>(3) Simonsen L. et al.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="457">
<prop type="lengthRatio">1.4230769230769231</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tinfirex l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="458">
<prop type="lengthRatio">1.5161290322580645</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi ttrattata l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="459">
<prop type="lengthRatio">0.9545454545454546</prop>
<tuv xml:lang="en">
<seg>non-productive cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kif jiġi manifatturat.</seg>
</tuv>
</tu>
<tu tuid="460">
<prop type="lengthRatio">1.6666666666666667</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin huwa sikur?</seg>
</tuv>
</tu>
<tu tuid="461">
<prop type="lengthRatio">0.8300653594771242</prop>
<tuv xml:lang="en">
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kwalunkwe persuna li mhijiex imlaqqma bil-vaċċin tal-pertussis, jew li l-istatus tat-tilqim tagħha mhuwiex aġġornat, tinsab f'riskju li taqbadha l-marda.</seg>
</tuv>
</tu>
<tu tuid="462">
<prop type="lengthRatio">0.625</prop>
<tuv xml:lang="en">
<seg>How can HPV be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="463">
<prop type="lengthRatio">2.0757575757575757</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jgħin biex tiġi eskluża l-possibbiltà li kienet koinċidenza jew li ġiet ikkawżata minn fatturi mhux relatati mal-vaċċin innifsu.</seg>
</tuv>
</tu>
<tu tuid="464">
<prop type="lengthRatio">0.9381443298969072</prop>
<tuv xml:lang="en">
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk in-nies jieqfu jitlaqqmu, ħafna minn dan il-mard u t-tifqigħat relatati jistgħu jirritornaw.</seg>
</tuv>
</tu>
<tu tuid="465">
<prop type="lengthRatio">2.141304347826087</prop>
<tuv xml:lang="en">
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar liema pajjiżi għandhom tilqim obbligatorju tinsab fl-Aġenda tal-Vaċċini .</seg>
</tuv>
</tu>
<tu tuid="466">
<prop type="lengthRatio">1.1216216216216217</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn sempliċiment jikkunsidraw ċirkostanzi u sistemi tas-saħħa differenti.</seg>
</tuv>
</tu>
<tu tuid="467">
<prop type="lengthRatio">1.6506024096385543</prop>
<tuv xml:lang="en">
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE jimplimenta l-programm ta' immunizzazzjoni tiegħu stess.</seg>
</tuv>
</tu>
<tu tuid="468">
<prop type="lengthRatio">1.2962962962962963</prop>
<tuv xml:lang="en">
<seg>Vaccination schedules in the EU/EEA</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sitwazzjoni tal-ħosba fl-UE</seg>
</tuv>
</tu>
<tu tuid="469">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>how it is manufactured.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kif tingħata t-tilqima;</seg>
</tuv>
</tu>
<tu tuid="470">
<prop type="lengthRatio">0.9583333333333334</prop>
<tuv xml:lang="en">
<seg>time since vaccination;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xorta jistgħu jirkupraw.</seg>
</tuv>
</tu>
<tu tuid="471">
<prop type="lengthRatio">1.6304347826086956</prop>
<tuv xml:lang="en">
<seg>small white spots may also appear on the gums and the inside of the cheeks.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Illum il-ġurnata, hemm tilqim għal ħafna mard.</seg>
</tuv>
</tu>
<tu tuid="472">
<prop type="lengthRatio">1.2391304347826086</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipprevjeni lin-nies milli jkollhom is-sintomi tal-marda, li jistgħu jkunu severi.</seg>
</tuv>
</tu>
</body>
</tmx>
|